

Gut microbiota and colonization resistance against bacterial enteric infection

Ducarmon, Q. R.; Zwitterink, R. D.; Hornung, B. V. H.; van Schaik, W.; Young, V. B.; Kuijper, E. J.

DOI:

[10.1128/MMBR.00007-19](https://doi.org/10.1128/MMBR.00007-19)

License:

None: All rights reserved

Document Version

Peer reviewed version

Citation for published version (Harvard):

Ducarmon, QR, Zwitterink, RD, Hornung, BVH, van Schaik, W, Young, VB & Kuijper, EJ 2019, 'Gut microbiota and colonization resistance against bacterial enteric infection', *Microbiology and Molecular Biology Reviews*, vol. 83, no. 3, e00007-19, pp. e00007-e00019. <https://doi.org/10.1128/MMBR.00007-19>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Checked for eligibility: 05/07/2019

Gut Microbiota and Colonization Resistance against Bacterial Enteric Infection, Q. R. Ducarmon, R. D. Zwitterink, B. V. H. Hornung, W. van Schaik, V. B. Young, E. J. Kuijper, *Microbiology and Molecular Biology Reviews* Jun 2019, 83 (3) e00007-19;

DOI: 10.1128/MMBR.00007-19

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

1 Gut microbiota and colonization resistance against bacterial enteric infection

2 Q.R. Ducarmon,^{a,b,#} R.D. Zwartink,^{a,b} B.V.H. Hornung,^{a,b} W. van Schaik,^c V.B.
3 Young,^{d,e} E.J. Kuijper^{a,b,f,g}

4 ^aCenter for Microbiome Analyses and Therapeutics, Leiden University Medical
5 Center, Leiden, Netherlands

6 ^bExperimental Bacteriology, Department of Medical Microbiology, Leiden University
7 Medical Center, Leiden, Netherlands

8 ^cInstitute of Microbiology and Infection, University of Birmingham, Birmingham, UK

9 ^dDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor,
10 Michigan, USA

11 ^eDepartment of Internal Medicine/Infectious Diseases Division, University of
12 Michigan Medical Center, Ann Arbor, Michigan, USA

13 ^fClinical Microbiology Laboratory, Department of Medical Microbiology, Leiden
14 University Medical Center, Leiden, Netherlands

15 ^gNetherlands Donor Feces Bank, Leiden, Netherlands

16
17 Running Head: Gut microbiota, colonization resistance and infection

18 # Address correspondence to Quinten R. Ducarmon, q.r.ducarmon@lumc.nl

20	SUMMARY	3
21	INTRODUCTION	4
22	MECHANISMS PROVIDING COLONIZATION RESISTANCE	5
23	Short-chain fatty acids	5
24	Bile acids	6
25	Bacteriocins	7
26	Nutrient competition	10
27	Mucus layers	11
28	Bacteriophages	13
29	EFFECTS OF VARIOUS NON-ANTIBIOTIC DRUGS ON GUT COLONIZATION	
30	RESISTANCE	14
31	Proton-pump inhibitors	14
32	Antidiabetics	16
33	Antipsychotics	16
34	COLONIZATION RESISTANCE TOWARDS SPECIFIC BACTERIAL ENTERIC	
35	PATHOGENS	18
36	<i>C. difficile</i>	19
37	<i>S. Typhimurium</i>	22
38	Enterohemorrhagic <i>E. coli</i>	25
39	<i>S. flexneri</i>	29
40	<i>C. jejuni</i>	31
41	<i>V. cholerae</i>	35
42	<i>Y. enterocolitica</i>	38
43	<i>L. monocytogenes</i>	41
44	Bacterial defense mechanisms against bacteriophages	44
45	CONCLUDING REMARKS	48
46	ACKNOWLEDGEMENTS	49
47	REFERENCES	50
48	FIGURE LEGENDS	81
49		
50		

SUMMARY

The gut microbiome is critical in providing resistance against colonization by exogenous microorganisms. The mechanisms via which the gut microbiota provides colonization resistance (CR) have not been fully elucidated, but include secretion of antimicrobial products, nutrient competition, support of gut barrier integrity and bacteriophage deployment. However, bacterial enteric infections are an important cause of disease globally, indicating that microbiota-mediated CR can be disturbed, and become ineffective. Changes in microbiota composition, and potential subsequent disruption of CR, can be caused by various drugs, such as antibiotics, proton pump inhibitors, antidiabetics and antipsychotics, thereby providing opportunities for exogenous pathogens to colonize the gut and ultimately cause infection. In addition, the most prevalent bacterial enteropathogens, including *Clostridioides difficile*, *Salmonella enterica* serovar Typhimurium, enterohemorrhagic *Escherichia coli*, *Shigella flexneri*, *Campylobacter jejuni*, *Vibrio cholerae*, *Yersinia enterocolitica* and *Listeria monocytogenes*, can employ a wide array of mechanisms to overcome colonization resistance. This review aims to summarize current knowledge on how the gut microbiota can mediate colonization resistance against bacterial enteric infection, and on how bacterial enteropathogens can overcome this resistance.

KEYWORDS colonization resistance, bacterial enteric infection, enteric pathogens, gut microbiota, microbiome, nutrient competition, mucus layer, bile acids, bacteriocins, short-chain fatty acids, bacteriophages, proton-pump inhibitors, metformin, antipsychotics

INTRODUCTION

The human gastrointestinal tract is colonized by an enormous number of microbes, collectively termed gut microbiota, including bacteria, viruses, fungi, archaea and protozoa. Bacteria achieve the highest cell density, estimated to be approximately 10^{11} bacteria/ml in the colon (1). Research has long focused on pathogenicity of microbes and not on their potential beneficial roles for human health. Beneficial roles include aiding in immune system maturation, production of short-chain fatty acids (SCFAs), vitamin synthesis and providing a barrier against colonization with potential pathogens (2). Additionally, the gut microbiota has extensive interactions with our immune system and it has been associated with many immune-mediated diseases both in and outside of the gut (3-5). Over the last ten years, there has been an increased interest in elucidating the bidirectional relationship between gut microbiota and human health and disease. This has been partly propelled by improved sequencing technologies, allowing the profiling of entire microbial communities at high efficiency and low costs (6).

Hundreds of different bacterial species inhabiting the healthy human gut have been identified (7, 8). Initial studies seeking to elucidate the relationship between human microbiota and health and disease were largely observational; gut microbiota composition would be compared between diseased and healthy groups and subsequently associated with clinical markers (9). Currently, the field is moving towards more functional and mechanistic studies by including other -omics techniques.

In healthy individuals, the gut microbiota provides protection against infection by deploying multiple mechanisms including secretion of antimicrobial products, nutrient competition, support of epithelial barrier integrity, bacteriophage deployment, and

immune activation. Together, these mechanisms contribute to resistance against colonization of exogenous microorganisms (colonization resistance, CR) (10). However, also in absence of a fully functional immune system, the gut microbiota can provide a crucial and nonredundant protection against a potentially lethal pathogen (11). This review will discuss the mechanisms used by gut microbiota to provide CR, the impact of various drugs on gut microbiota and thereby CR, and the strategies of specific bacterial pathogens to overcome CR and ultimately cause enteric infection.

MECHANISMS PROVIDING COLONIZATION RESISTANCE

The gut microbiota produces various products with antimicrobial effects, including SCFAs, secondary bile acids and bacteriocins. Each of these contribute to CR in a product-specific manner. The following section describes their general mechanisms of action. The contribution of the immune system in conferring CR has been extensively reviewed elsewhere and is outside the scope of this review (12, 13).

Short-chain fatty acids

SCFAs are mainly produced by bacteria through fermentation of non-digestible carbohydrates (Fig. 1) (14). The three main SCFAs are acetate, propionate and butyrate, constituting 90-95% of the total SCFA pool (15). During homeostatic conditions, butyrate is the main nutrient for enterocytes and is metabolized through β -oxidation. Hereby, an anaerobic milieu inside the gut can be maintained (16). SCFAs can impair bacterial growth by affecting intracellular pH and metabolic functioning. SCFA concentrations have been shown to inversely relate to pH

throughout different regions of the gut (17). At lower pH, SCFAs are more prevalent in their non-ionized form and these non-ionized acids can diffuse across the bacterial membrane into the cytoplasm. Within the cytoplasm they will dissociate, resulting in a build-up of anions and protons leading to a lower intracellular pH (18).

In presence of acetate, metabolic functioning of *Escherichia coli* could be impaired by preventing biosynthesis of methionine, leading to accumulation of toxic homocysteine and growth inhibition. Growth inhibition was partly relieved by supplementing the growth medium with methionine, showing that this metabolic dysfunction is one of the factors by which SCFAs impair bacterial growth (19).

Bile acids

Bile acids, possessing antimicrobial properties, are produced by the liver and excreted in the intestinal tract to aid in the digestion of dietary lipids. After production of primary bile acids in the liver, they are subsequently conjugated with glycine or taurine, to increase solubility (20). These are then stored in the gallbladder, and upon food intake, are released into the duodenum to increase solubilization of ingested lipids. A large part of conjugated primary bile acids is reabsorbed in the distal ileum (50-90%), while the remainder can be subjected to bacterial metabolism in the colon (20). Here, conjugated bile acids can be deconjugated by bile salt hydrolases (BSH), which are abundantly present in the gut microbiome (21). Deconjugated primary bile acids can subsequently be converted into the two main secondary bile acids, deoxycholic acid and lithocholic acid, by few bacteria, mostly *Clostridium* species, via 7 α -dehydroxylation through a complex biochemical pathway (21-23) (Fig. 1). A crucial step during the conversion is encoded by the *baiCD* gene, which is found in several *Clostridium* strains, including *Clostridium scindens* (24).

Deoxycholic acid is bactericidal to many bacteria, including *Staphylococcus aureus*, *Bacteroides thetaiotaomicron*, *Clostridioides difficile*, bifidobacteria and lactobacilli by membrane disruption and subsequent leakage of cellular content (25-28).

The importance of bacteria for conversion of primary bile acids was demonstrated by investigating bile acid profiles in germ-free mice, where no secondary bile acids could be measured (29). Very few colonic bacteria, less than 0.025% of total gut microbiota, are capable of performing 7 α -dehydroxylation (23, 30). One of these bacteria, *C. scindens*, is associated with colonization resistance against *C. difficile* through secondary bile acid production (22, 31). A follow-up *in vivo* study demonstrated that *C. scindens* provided CR in the first day post infection (p.i), but protection and secondary bile acid production was lost at 72 p.i (32). *C. scindens* on its own was also not sufficient to inhibit *C. difficile* outgrowth in humans (33). Together, these studies suggest that *C. scindens* either requires cooperation with other secondary-bile acid producing bacteria or that other mechanisms were involved in providing CR. The secondary bile acid lithocholic acid may exert its antimicrobial effects, and potentially its effects on CR, in an indirect manner. Lithocholic acid has been shown to enhance transcription for the antimicrobial peptide LL-37, in gut epithelium using a HT-29 cell line (34). However, no increased mRNA transcription nor protein translation of LL-37 was observed in another study using a Caco2 cell line (35).

Bacteriocins

Bacteriocins are short, toxic peptides produced by specific bacterial species that can inhibit colonization and growth of other species (36) (Fig. 1). Their mechanisms of action are multifold and include disturbing RNA and DNA metabolism, and killing

cells through pore formation in the cell membrane (37-40). Bacteriocins can be divided into those produced by Gram-positive bacteria, and those produced by Gram-negative bacteria. Further classification of bacteriocins has been extensively discussed elsewhere, (41, 42). Bacteriocins produced by Gram-positive bacteria are mostly produced by lactic acid bacteria (e.g. *Lactococcus* and *Lactobacillus*) and some *Streptococcus* species, and are further subdivided into three major classes on the basis of the molecular weight of the bacteriocins and the presence of post-translational modifications (42). Bacteriocins produced by Gram-negative bacteria, mostly by *Enterobacteriaceae*, can be broadly divided into high molecular weight proteins (colicins) and lower molecular weight peptides (microcins) (41).

The lantibiotic nisin is the best studied bacteriocin and is produced by *Lactococcus lactis* strains. It has potent activity against many Gram-positive bacteria but has much less intrinsic activity against Gram-negative organisms (43-45). By itself, nisin does not induce growth inhibition of Gram-negative bacteria, since binding to lipid II – the main target – is prevented by the outer bacterial membrane (46). Therefore, studies have used different methods to overcome this problem by combining nisin with chelating agents like EDTA, antibiotics and engineered nisin peptides (47-52). These compounds can destabilize the outer membrane, allowing nisin to exert its damaging effect (53, 54).

Several *in vivo* models have confirmed the potency of bacteriocins in providing CR. *Lactobacillus salivarius* UCC 118, which produces the bacteriocin Abp118, was able to significantly protect mice from infection by direct killing of *Listeria monocytogenes*, while an UCC 118 mutant could not, confirming the protective role of Abp118 against this food-borne pathogen (55).

197 Another example is *Bacillus thuringiensis* DPC 6431, which produces the bacteriocin
198 thuricin (36). Thuricin targets several *C. difficile* strains, including the highly virulent
199 PCR ribotype 027. *In vitro*, its activity was more potent than metronidazole, the
200 common treatment for *C. difficile* infection (56). In a colon model system,
201 metronidazole, vancomycin and thuricin all effectively reduced *C. difficile* levels.
202 However, thuricin has the advantage of conserving gut microbiota composition. This
203 is highly relevant, as a disturbed microbiota is associated with increased
204 susceptibility to infection (57, 58).

205 *Enterobacteriaceae* members can produce specific bacteriocins called colicins and
206 one example, colicin F_Y, is encoded by the *Yersinia frederiksenii* Y27601 plasmid.
207 Recombinant *E. coli* strains, capable of producing colicin F_Y, were shown to be highly
208 effective against *Yersinia enterocolitica in vitro* (59). *In vivo* experiments were
209 performed by first administering the recombinant *E. coli* strains, after which mice
210 were infected with *Y. enterocolitica*. In mice with a normal gut microbiota the
211 recombinant strains did not inhibit *Y. enterocolitica* infection, while infection was
212 effectively reduced in mice pre-treated with streptomycin (59). This was most
213 probably the result of increased colonization capacity of recombinant *E. coli* in the
214 inflamed gut, while the normal gut microbiota provided sufficient CR to prevent *E.*
215 *coli* colonization (59).

216 Microcins are also produced by *Enterobacteriaceae*, but differ from colicins in
217 several ways (60). For example, microcins are of much smaller size (<10 kDa) and
218 microcin production is not lethal to the producing bacterium, in contrast to colicin
219 production (60). *E. coli* Nissle 1917, capable of producing microcin M and microcin
220 H47, could significantly inhibit *Salmonella enterica* serovar Typhimurium *in vitro* and
221 *in vivo* (61). This inhibition was however only seen during intestinal inflammation,

during which *S. Typhimurium* expresses siderophores to scavenge iron from an iron-depleted environment. As microcins are able to conjugate to siderophores and *S. Typhimurium* takes up the siderophore during iron scavenging, microcins are introduced into the bacterial cell in a Trojan-horse like manner (62).

In silico identification of bacteriocin gene clusters shows that much remains to be discovered in this area, as 74 clusters were identified in the gut microbiota (63). Not all of these clusters may be active *in vivo*, but it illustrates the potential relevance of bacteriocin production by the gut microbiota to provide colonization resistance.

Nutrient competition

Bacteria have to compete for nutrients present in the gut. This is especially relevant for bacterial strains belonging to the same species, as they will often require similar nutrients. The importance of nutrient competition in providing CR has been shown in multiple studies using multiple *E. coli* strains (64-67). Indigenous *E. coli* strains compete with pathogenic *E. coli* O157:H7 for the amino acid proline (64). In fecal suspensions, depletion of the proline pool by high-proline-utilizing *E. coli* strains inhibited growth of pathogenic *E. coli*. This inhibition could be reversed by adding proline to the medium, thereby confirming nutrient competition between the strains (64). In addition to amino acids, different *E. coli* strains use distinct sugars present in the intestinal mucus (65). When two commensal *E. coli* strains were present in the mouse gut that together utilize the same sugars as *E. coli* O157:H7, *E. coli* O157:H7 was unable to colonize after it was administered to these mice. However, *E. coli* O157:H7 successfully colonized when only one of these commensals was present. This indicated that the two commensals complement each other to sufficiently deplete all sugars used by this pathogenic *E. coli* strain (66). Nutrient competition is

not limited to macronutrients, but can extend to micronutrients such as iron. *S. Typhimurium* is known to take up large amounts of iron from the inflamed gut during infection (67). Upon a single administration of the probiotic *E. coli* Nissle 1917, which was proposed to scavenge iron very efficiently, *S. Typhimurium* levels were reduced more than two log-fold during infection via the limitation of iron availability. Administration of *E. coli* Nissle 1917 prior to infection with *S. Typhimurium* led to a 445-fold lower colonization (67).

Finally, genome-scale metabolic models have been used to reconstruct microbiome-wide metabolic networks, which could partly predict which species utilize specific compounds from their environment (68). These models have been used to study nutrient utilization by *C. difficile*, which will be described in the section on this organism below.

Together, these studies show that colonization resistance by nutrient competition is most effective when microbiota take up key nutrients that are required by the pathogen (Fig. 1). Future strategies could therefore aim at administering probiotic strains that are able to outcompete pathogens for specific nutrients. This is especially relevant at times of gut microbiota disturbances, e.g. during and following an antibiotic treatment, as this is the time window where it is easiest for exogenous bacteria to colonize the GI tract.

Mucus layers

The gut barrier consists of the inner and outer mucus layer, the epithelial barrier and its related immune barrier. It is out of the scope of this review to discuss the full immunological characteristics of the epithelial barrier, the highly complex host-microbe interactions occurring at the mucus layer and host-associated genetic

polymorphisms associated with mucus layer composition, as these have been extensively described elsewhere (12, 13, 69, 70). Instead, a general description with various examples of how the mucus layer provides CR will be given.

The inner mucus layer is impenetrable and firmly attached to the epithelium, forming a physical barrier for bacteria thereby preventing direct interaction with the epithelial layer and a potential inflammatory response (71, 72). Commensal gut microbes reside and metabolize nutrients in the nonattached outer mucus layer. Thinning of the mucus layer leads to an increased susceptibility for pathogen colonization, which can result from a Western-style diet deficient in microbiota-accessible-carbohydrates (MACs) (58). When MACs were scarce, mucus-degrading bacteria (*Akkermansia muciniphila* and *Bacteroides caccae*) fed on the outer mucus layer in a gnotobiotic mouse model, resulting in closer proximity of bacteria to the epithelial layer (58). The host adapts by increasing *muc2* expression, the main producer of intestinal mucin glycans, but fails to sufficiently do so. Inner mucus layer damage could however be reversed by administration of *Bifidobacterium longum*, perhaps due to stimulation of mucus generation (73).

The composition of the microbiota is thus a contributing factor to the integrity of the mucus barrier. Genetically identical mice housed in different rooms at the same facility showed a distinct microbiota composition, with one group of mice showing a more penetrable barrier (74). When FMT was performed on germ-free mice, they displayed the same barrier function as their respective donor. No specific microbes were identified to be responsible for the change in observed barrier function (74).

In conclusion, the mucus layers provide a first barrier of defense against colonization of exogenous microorganisms. Diet has been shown to be an important factor for

proper functioning of this layer, suggesting that dietary intervention, or specific pro- and prebiotics, may be a future therapeutic option.

Bacteriophages

Bacteriophages are the most abundant microorganisms on our planet and are also highly present in the human gut (75, 76). Bacteriophages have been proposed as potential alternatives to antibiotics, as they are highly specific, only targeting a single or a few bacterial strains thereby minimizing the impact on commensal members of the microbiota (75, 77) (Fig. 1). Their complex interactions in the intestine with both host immunity and bacterial inhabitants are starting to be explored, but much remains to be elucidated (76). Here, we will focus on their relationship with bacterial enteropathogens.

Vibrio cholerae infection could be controlled using a prophylactic phage cocktail in mice and rabbits (78). This prophylactic cocktail killed *V. cholerae* *in vitro*, reduced colonization of *V. cholerae* in the mouse gut and prevented cholera-like diarrhea in rabbits. Importantly, the authors suggest that the concentration of phages in the gut is an important criterion for successful prevention of infection, as timing between phage cocktail administration and *V. cholerae* inoculation was associated with treatment outcome (78). Similar findings have been demonstrated for *Campylobacter jejuni* colonization in chickens, where a phage cocktail reduced *C. jejuni* levels several orders of magnitude (79).

Bacteriophages can also confer a competitive advantage for commensals. *Enterococcus faecalis* V583 harbors phages that infect and kill other *E. faecalis* strains, thereby creating a niche for *E. faecalis* V583 (80).

Phages play an important role in excluding specific gut bacteria and can thereby contribute to CR. Therapeutic use in humans is not yet performed at a wide scale in the Western world, as sufficient evidence for their safety and efficacy is still lacking (81). However, recent case reports indicate that bacteriophage treatment has definite future potential for treating multi-drug resistant bacteria (82, 83).

EFFECTS OF VARIOUS NON-ANTIBIOTIC DRUGS ON GUT COLONIZATION RESISTANCE

Antibiotics are long known for their deleterious effect on gut microbiota. Recently, various other drugs have come to attention for their impact on our microbial ecosystem. As effects of antibiotics have been extensively reviewed elsewhere (84, 85), the focus in the current review will be on non-antibiotic drugs, namely proton-pump inhibitors (PPIs), antidiabetics and antipsychotics.

Proton-pump inhibitors

PPIs inhibit gastric acid production and are among the most prescribed drugs in Western countries (86). A significant association between long-term use of PPIs and the risk on several bacterial enteric infections has been demonstrated in multiple systematic reviews (87-90).

Several studies have associated PPI use with microbiota alterations that may specifically predispose to *C. difficile* infection and to small intestinal bacterial outgrowth (91-95). Especially taxa prevalent in oral microbiota (e.g. *Streptococcus*) were associated with PPI use, likely resulting from increased gastric pH and thereby allowing for colonization of these bacteria further down the gastrointestinal tract (91-

94). Administering PPIs to twelve healthy volunteers for four weeks did not result in changes in diversity or changes in overall microbiota composition. However, abundance of specific taxa associated with *C. difficile* infection and gastrointestinal bacterial overgrowth increased, thereby potentially lowering colonization resistance against *C. difficile* (91).

Results of two mouse studies suggest that the reduced bactericidal effect, due to increased stomach pH, may be the most important factor for increased enteric infection risk. Mice received PPIs seven days prior to infection with the murine pathogen *Citrobacter rodentium*, which resulted in increased numbers of *C. rodentium* in the cecum one hour post inoculation as compared to control mice (96). Similar results were observed in another study where treatment of mice with PPIs led to increased colonization of vancomycin-resistant enterococci and *Klebsiella pneumoniae* (97). In spite of its general acceptance as a model for gut disturbances, it is important to note that mice were pre-treated with clindamycin, which may limit generalizability (97). This is an important issue when studying effects of PPIs, as the combined use of medication in the human population complicates the study of the effects of PPIs on microbiota and CR. Even though large-scale studies have adjusted for cofounders to filter out the effect of PPIs on the gut microbiota, this does not represent a mechanistic study where only PPIs would be administered (92, 98). Therefore, more mechanistic studies investigating how PPIs increase the risk for enteric infection are required. These studies should then exclusively administer PPIs to healthy human volunteers or animals.

Antidiabetics

Metformin is the primary prescribed drug for treatment of type II diabetes mellitus (T2DM) and mainly acts by reducing hepatic glucose production, thereby lowering blood glucose levels (99). The current increase in the number of T2DM patients is unprecedented and it is therefore crucial to evaluate metformin's effect on gut microbiota and colonization resistance (100).

The microbiota of T2DM patients is, amongst other changes, characterized by a depletion in butyrate-producing bacteria (101, 102). Metformin administration increased both the abundance of butyrate and other SCFA-producing bacteria, as well as fecal SCFA levels and may thus contribute to colonization resistance. The underlying mechanisms remain unknown (101, 103).

Another effect of metformin has been studied in an *in vitro* model, where it was found to reduce tight junction dysfunction of the gut barrier by preventing TNF- α induced damage to tight junctions (104). Similar findings for improvement of tight junction dysfunction were demonstrated using two *in vivo* models, one using interleukin-10 deficient mice and one using a colitis mouse model (105, 106). As tight junctions are a critical part of epithelial barrier integrity, alleviating their impaired functioning likely improves CR.

In conclusion, metformin may have beneficial effects on CR, as its ability to raise SCFA concentrations and improved tight junction function suggests. The effects of metformin on gut microbiota and CR in healthy organisms needs further evaluation.

Antipsychotics

The interest in whether antipsychotics affect gut microbiota composition and colonization resistance may surge after a recent publication demonstrating that

antipsychotics target microbes based on their structural composition (107). This led to the suggestion that antibacterial activity may not simply be a side effect of antipsychotics, but can be part of their mechanism of action (107). Various antipsychotics have been investigated for their antibacterial effects, of which several will be highlighted here.

In an *in vitro* model, olanzapine has been demonstrated to completely inhibit growth of two potentially pathogenic bacteria, *E. coli* and *E. faecalis* (108). Pimozide has been shown to inhibit internalization of several bacteria, including *L. monocytogenes* (109). An *in vitro* screening test evaluated effects of fluphenazine on 482 bacterial strains, belonging to ten different genera. Growth inhibition was demonstrated in multiple species, including five out of six *Bacillus spp.*, 95 out of 164 staphylococci, 138 out of 153 *V. cholerae* strains and several *Salmonella* species. Significant protection by administering fluphenazine was shown in a mouse model infected with *S. Typhimurium*, as viable cells in several organs was lower and overall survival was higher as compared to controls (110).

Antipsychotics can also be used in combination with antibiotics, to exert a synergistic antibacterial effect. Flupenthixol dihydrochloride (FD) was demonstrated to have antibacterial activity, both *in vitro* and *in vivo* (111). Co-administration of FD and penicillin yielded extra protection against *S. Typhimurium* as compared to singular administration of either drug. (111). As antipsychotics have only recently been recognized for their potential antimicrobial effects, studies have only looked at the effects on pathogens. It is likely that gut commensals are also affected by these drugs, but future studies will have to confirm this hypothesis.

Apart from their potential antibacterial effects, several antipsychotics were shown to increase intestinal permeability in the distal ileum in rats, and therefore showing a

possibly detrimental effect on CR (112). Curiously enough, use of antidepressants was associated with increased risk of *C. difficile* infection development, although no underlying mechanism has been elucidated yet (113).

In conclusion, antipsychotics have definite antibacterial effects, but, to our knowledge, no studies have yet been performed regarding their effects on colonization resistance and bacterial enteric infection *in vivo*.

COLONIZATION RESISTANCE TOWARDS SPECIFIC BACTERIAL ENTERIC PATHOGENS

Other than antibiotic resistance acquisition, enteric pathogens possess multiple virulence factors to overcome CR and cause infection. Some of these factors are common and apply to many bacterial species, others are organism-specific. Mechanisms implicated in antibiotic resistance development include horizontal gene transfer, mutational resistance and altering structure and thereby efficacy of the antibiotic molecule. Full reviews describing these mechanisms in depth can be found elsewhere (114, 115). Here, the main focus will be on how several of the most prevalent and dangerous bacterial enteropathogens overcome the mechanisms providing CR as described herein, namely secretion of antimicrobial products, nutrient competition, mucus barrier integrity and bacteriophage deployment. As insufficient knowledge is available on how each specific enteropathogen overcomes CR by rendering bacteriophages ineffective, apart from the well-known and conserved CRISPR-Cas, an overview of the currently known bacterial defense mechanisms will be given at the end of this review.

C. difficile

C. difficile-associated diarrhea is the most common hospital-acquired infection, causing more than 450,000 diarrheal cases per year in the United States alone (116). Clinical symptoms can range from self-limiting diarrhea to bloody diarrhea, pseudomembranous colitis and ultimately death (117). However, also in healthy individuals CR is not always successful against this opportunistic pathogen, resulting in asymptomatic colonization in 2-15% of the healthy population (118). The reason why some asymptomatically colonized patients do not develop infection, while others do, may well be found in the gut microbiome, although no mechanisms have yet been elucidated. *C. difficile* contains a pathogenicity locus with the information to produce its two major toxins, TcdA and TcdB. The significance of a third toxin, called binary toxin, is less clear. Toxin production in the colon is facilitated by disruption of the native gut microbiota, for instance through antibiotic use (119).

Effects of SCFAs on *C. difficile* throughout its life cycle are currently unclear (120-122). In an antibiotic-treated mouse model, decreased SCFA levels were associated with impaired CR against *C. difficile* (120). CR was subsequently restored six weeks after ending antibiotic treatment with a concomitant increase in SCFAs, probably resulting from restoration of the fermentative activity of the microbiota (120). Restoration of SCFA levels is also seen as an effect after fecal microbiota transplantations in humans (122). However, SCFA supplementation could not induce a significant decrease in *C. difficile* shedding levels up to six weeks post infection (121). No study has yet investigated whether *C. difficile* possesses any mechanisms by which it becomes resistant against the effects of SCFAs, which warrants further research.

466

467 Compared to the effects of SCFAs, there is more clarity on the effects of bile acids
468 on *C. difficile*. Secondary bile acids are toxic to both *C. difficile* spores and vegetative
469 cells, while primary bile acids generally stimulate growth and spore germination
470 (123-125). During antibiotic treatment, conversion of primary into secondary bile
471 acids is suppressed and the reduction of secondary bile acids leads to a more
472 favorable environment for *C. difficile* (120). In addition, *C. difficile* isolates causing
473 most severe disease in mice were also the isolates that showed highest resistance
474 against lithocholic acid *in vitro* (126). A relationship between disease score and
475 deoxycholic acid could not be shown (126). Secondary bile acid resistance may be
476 strain-dependent, but further research is warranted to draw this conclusion with
477 certainty.

478

479 Intrinsic anti-bacteriocin properties have been described for *C. difficile* (127, 128).
480 Nisin can inhibit growth of vegetative cells and prevent spore germination of *C.*
481 *difficile in vitro* (44). However, this does not hold for all *C. difficile* strains, as the
482 mutant strain MC119 had normal growth in sub-lethal concentrations. It was
483 demonstrated that this resistance was at least partly due to export of nisin by an
484 ABC-transporter (127). Another identified mechanism was a net positive charge on
485 the bacterial cell surface resulting in lower efficacy of nisin, since nisin is attracted to
486 a low negative charge on the cell surface (128).

487

488 Using genome-scale metabolic models in antibiotic-treated mice, it was
489 demonstrated that *C. difficile* does not necessarily compete for specific nutrients
490 against specialized bacteria, but that it adapts to utilize a wide array of nutrients. This

allows for colonization of diverse microbiomes, wherein *C. difficile* is not limited to a specific nutrient niche (129). A follow-up study, also using a multi-omics approach, showed that *C. difficile* alters transcriptional activity of especially low abundant taxa. The main genes showing decreased transcription in these low abundant taxa during infection, as compared to mock infected mice, were carbohydrate-acquisition and utilization genes. A possible reason for this could be that *C. difficile* attempts to create its own nutrient niche to facilitate colonization (130).

However, others have found specific nutrients that may be important for *C. difficile* colonization and/or outgrowth. Three highly virulent ribotypes (RT), RT017, RT027 and RT078, have recently been demonstrated to utilize trehalose as a nutrient source (131, 132). This was confirmed in a mouse model, where mice were challenged with spores of either RT027 or a non-trehalose metabolizing ribotype. After trehalose administration, RT027 mice showed higher mortality in a dose-dependent manner (131).

C. difficile post-antibiotic outgrowth depends partly on the production of succinate and sialic acid by commensals. *B. thetaiotaomicron* is capable of metabolizing polysaccharides and thereby produces sialic acid. Upon inoculation with *C. difficile*, monocolonized *B. thetaiotaomicron* mice had approximately a five times higher density of *C. difficile* in feces as compared to germ-free mice (133). Expression levels of genes involved in sialic acid metabolism were increased in the *B. thetaiotaomicron* model, and, as expected, a sialidase-deficient *B. thetaiotaomicron* mutant led to highly reduced production of sialic acid and *C. difficile* density was lower (133).

Density of *C. difficile* was higher in *B. thetaiotaomicron* mice fed a polysaccharide-rich diet as compared to a chow diet (134). The succinate to butyrate pathway was

crucial for *C. difficile* expansion in *B. thetaiotaomicron* mice, as WT *C. difficile* was more effective in establishing infection than a succinate-transporter deficient *C. difficile* (134).

Micronutrient availability can affect virulence of *C. difficile*. High zinc levels have been demonstrated to exacerbate *C. difficile* infection in mouse models (135). Mice fed a high-zinc diet had higher toxin levels, higher pro-inflammatory cytokines levels and increased loss of barrier function. Furthermore, it was shown that calprotectin, a zinc-binding protein, was important for limiting zinc availability to *C. difficile* during infection (135).

Together, these studies demonstrate the importance of specific nutrients used by *C. difficile* to establish colonization and infection.

Efficient colonization of the epithelial barrier is made possible by flagella and pili (136, 137). When mice were inoculated with flagellated or non-flagellated *C. difficile* strains, higher levels of flagellated *C. difficile* were found in mouse cecum (136). The exact destination of non-flagellated *C. difficile* remained unknown, as levels were not measured in feces or in sections of the small intestine. Regarding pili, it has been shown that type IV pili were not playing a role in initial colonization, but were crucial for epithelial adherence and long-lasting infection (137).

S. Typhimurium

S. Typhimurium is a nontyphoidal *Salmonella* and an important cause of gastroenteritis in humans. It was estimated that globally 3.4 million invasive nontyphoidal *Salmonella* infections occur each year, of which 65.2% are attributable to serovar Typhimurium (138). It mostly causes self-limiting, non-bloody diarrhea in

otherwise healthy individuals. However, it can lead to bloodstream infections and metastatic spread with eventually death in especially infants and immunocompromised individuals (138, 139). *S. Typhimurium* contains two pathogenicity islands, SPI1 and SPI2. SPI1 mostly contains information for causing intestinal disease and cell invasion, while SPI2 is necessary for intracellular survival (140).

Effects of SCFAs on *S. Typhimurium* are not yet well defined. Butyrate and propionate have been demonstrated to reduce expression of invasion genes, while acetate increased their expression in *S. Typhimurium* (141, 142). However, conflicting results exist. A *S. Typhimurium* knockout mutant, unable to metabolize butyrate, caused less inflammation than a WT *S. Typhimurium*, suggesting that butyrate is crucial for *S. Typhimurium* virulence (143). Furthermore, this study demonstrated that butyrate was necessary for expression of invasion genes in mouse models. In contrast, propionate inhibited *S. Typhimurium* in a dose-dependent manner *in vitro*, probably due to disturbance of intracellular pH (144). In an *in vivo* setting, it was demonstrated that a cocktail of propionate-producing *Bacteroides* species was sufficient to mediate CR against *S. Typhimurium* (144).

S. Typhimurium has developed mechanisms to overcome bile acids encountered in the gut. When exposed to individual bile acids at sub-lethal levels *in vitro*, it can become resistant to originally lethal levels by changing gene and protein expression of several virulence regulators (145, 146). In addition, it has been demonstrated that a mixture of cholate and deoxycholate confers a synergistic inhibition on invasion gene expression in *S. Typhimurium* (147).

566

567 Innate resistance of *S. Typhimurium* against bacteriocins produced by Gram-positive
568 bacteria is naturally conferred through its Gram-negative outer membrane (148).

569

570 Usage of nutrients produced by gut microbiota is believed to facilitate *S.*
571 *Typhimurium* outgrowth. By causing inflammation and thereby altering microbiota
572 composition, *S. Typhimurium* provides itself with a competitive advantage (149, 150).
573 Metabolic profiling in mice showed increased luminal lactate levels in the inflamed
574 gut during *S. Typhimurium* infection, which could result from a depletion in butyrate-
575 producing bacteria (149). When butyrate is scarce, enterocytes switch to glycolysis
576 with lactate as end product. Lactate is an important nutrient for *S. Typhimurium*, as
577 indicated by decreased colonization of cecal and colonic lumen by a *S. Typhimurium*
578 mutant lacking two lactate dehydrogenases (149).

579 As explained in the introduction, an anaerobic milieu is maintained in the gut during
580 homeostatic conditions. However, diffusion of oxygen from the tissue to the lumen is
581 enabled by inflammation caused by *S. Typhimurium*, which alters enterocyte
582 metabolism (151). Oxygen can then be used by *S. Typhimurium* to ferment several
583 carbohydrates through respiration (152-155).

584 In conclusion, these findings suggest that *S. Typhimurium* creates its own niche in
585 the gut by causing inflammation, subsequently shifting microbiota composition and
586 thereby nutrient availability, so that it can optimally colonize and expand.

587

588 An intact and well-functioning mucus layer is crucial for protection against *S.*
589 *Typhimurium* infection. WT mice infected with the attenuated $\Delta aroA$ strain, which
590 causes severe colitis, showed increased *muc2* gene expression and MUC2

production (156). Mortality and morbidity was high in $\Delta muc2$ mice and higher numbers of the pathogen were found in their liver, ceca and close to the epithelial layer (156).

S. Typhimurium may profit from mucin-degrading commensal microbiota. In a gnotobiotic mouse model, complementation with mucin degrading *A. muciniphila* during *S. Typhimurium* infection allowed *S. Typhimurium* to dominate the bacterial community five days p.i (157). This was not caused by an absolute increase in cell number, but by a decrease in other microbiota members. In addition, the complementation with *A. muciniphila* led to increased inflammation, as indicated by increased histopathology scores and protein and mRNA levels of pro-inflammatory cytokines. Although generally considered a beneficial bacterium, *A. muciniphila* exacerbated *S. Typhimurium* infection by thinning the mucus layer, thereby promoting translocation of the pathogen to the epithelial layer (157).

Enterohemorrhagic *E. coli*

Shiga-toxin producing *E. coli* (STEC) comprises a group of *E. coli* strains capable of producing Shiga-toxins. Enterohemorrhagic *E. coli* (EHEC) is a subgroup of STEC causing more severe disease, often with complications. Each year, approximately 100,000 people are infected by the most common EHEC serotype, O157:H7 (158). Clinical presentation includes abdominal pain and bloody diarrhea which can progress into toxin-mediated hemolytic uremic syndrome (159). Virulence of EHEC strains is mostly encoded by Shiga toxin genes, *stx1* and *stx2*, and by locus of enterocyte effacement (*lee*) genes, which are imperative for initial attachment to epithelial cells (160).

At present, outcomes regarding the effects of SCFAs on EHEC are mixed (161-165). LEE protein and gene expression was already enhanced at 1.25mM of butyrate, while for acetate and propionate, only minor changes were detected at 20mM, with acetate giving a repressive effect. In a separate growth experiment, acetate was more efficient in inhibiting growth of EHEC as compared to butyrate and propionate (162). Acetate was observed to have small repressive effects on EHEC in the study by Nakanishi *et al.*, and this was also found by Fukuda *et al.* (162, 165). Mice fed acetylated starch prior to infection showed higher fecal acetate levels and improved survival rate compared to starch-fed mice (165). Acetate also prevented gut barrier dysfunction as measured by transepithelial electrical resistance and prevented translocation of the Shiga toxin to the basolateral side of the epithelial cells (165). In Caco2 cells, EHEC epithelial adherence was 10-fold higher when grown on butyrate than on acetate or propionate (162). These results indicate that butyrate may be less effective in inhibiting EHEC growth and potentially colonization as compared to acetate and propionate, for which the exact pathways and genes involved have been elucidated (162, 163). In contrast, butyrate was found to be effective against EHEC in a pig model (161). Piglets given sodium butyrate two days prior to being infected with EHEC showed no symptoms 24 hours p.i, while the control group developed multiple signs of disease, e.g. histopathological signs of kidney damage. The sodium butyrate group did not show any signs of inflammation and shed less viable cells compared to the control group within 48h (161). *In vitro* assays demonstrated that butyrate enhanced bacterial clearance, ultimately making the authors suggest that butyrate can be developed as a new drug to treat EHEC (161).

641 EHEC has multiple traits to fight against the potentially deleterious effects of bile
642 acids. Bile acid mixtures upregulated gene expression of the AcrAB efflux pump and
643 downregulated *ompF*, a gene encoding for an outer membrane porin (166). In
644 addition, other genes responsible for limiting penetration of bile acids through the
645 membrane (*basR* and *basS*), were upregulated, and this effect was concentration-
646 dependent. Interestingly, the bile acid mixtures did slightly downregulate *stx2* subunit
647 genes, encoding for Shiga toxin production (166).

648

649 EHEC possesses natural resistance against bacteriocins, especially nisin, through its
650 Gram-negative outer membrane, as described in the chapter on bacteriocins. Three
651 EHEC strains were screened for, amongst others, potential resistance against
652 several colicinogenic *E. coli* strains (167). *In vitro*, resistance against *E. coli* strains
653 producing a single colicin was observed, but resistance was rarely observed against
654 multiple colicins and could never be linked to acquiring a specific plasmid (167).

655

656 Nutrient competition for proline and several sugars between EHEC and commensal
657 *E. coli* strains is described in the introductory section. In addition, ethanolamine (EA),
658 a source of carbon, nitrogen and energy for EHEC, has been investigated. It was
659 demonstrated that EA could diffuse across the bacterial membrane and that the *eut*
660 genes were crucial for metabolizing EA. *Eut* sequences were absent in native
661 bacterial genomes in the bovine gut, apart from commensal *E.coli*, indicating that EA
662 provides a nutrient niche for *E. coli*. When the *eutB* gene was knocked out in
663 EDL933, it was outcompeted by commensal *E. coli* due to its inability of utilizing EA,
664 indicating its critical importance for colonization (168).

665 During further transcriptomic investigations of EA utilization, it was noticed that
666 genes involved in gluconeogenesis were upregulated if no glucose was
667 supplemented. A knockout of two genes within the gluconeogenesis pathway led to a
668 growth defect in a coculture with the wildtype (169). This is in line with a previous
669 finding that optimal usage of gluconeogenic substrates by EDL933 is important for
670 colonization (170). Since this effect was seen in a medium consisting of bovine small
671 intestinal contents, the relevance for the human gut remains unclear (169).

672 Co-culturing of EHEC with *B. thetaiotaomicron* led to an upregulation of genes
673 involved in nutrient competition in EHEC as compared to culturing EHEC alone
674 (171). In addition, presence of *B. thetaiotaomicron* resulted in upregulation of
675 multiple virulence genes including *lee*, likely due to regulation of a transcription factor
676 involved in sensing carbon metabolite concentrations in the environment (171).
677 Using a combination of *in vitro* and *in vivo* methods, Pacheco *et al.* showed that
678 fucose cleaved from mucins by *B. thetaiotaomicron* could be an important nutrient for
679 upregulating virulence and intestinal colonization of EHEC (172). Interestingly,
680 fucose sensing and subsequent regulation of virulence genes was more important
681 for successful colonization than utilization of fucose for energy. This example
682 indicates that nutrients cannot only be utilized for energy, but that they can be
683 important environmental signals for properly regulating timing of virulence (172).

684

685 Human colonoid monolayers were used to study initial colonization mechanisms of
686 EHEC (173). This study showed that EHEC disturbs the tight junctions, preferentially
687 attaches to mucus producing cells and subsequently impairs the mucus layer (173).
688 In addition, by using various *in vitro* models, it was demonstrated that the

metalloprotease StcE, produced by EHEC, enables degradation of MUC2 in the inner mucus layer which may pave the way to the epithelial surface (174).

S. flexneri

Shigella infections mostly occur in developing countries, with *S. flexneri* as the most frequently found species (175). Annually, an estimated 164,000 people die of shigellosis worldwide (176). Clinical presentation includes a wide variety of symptoms, including severe diarrhea, possibly containing blood and mucus, and abdominal pain (160). *S. flexneri* contains a virulence plasmid (pINV) which is necessary for invasion of epithelial cells and intracellular survival (160).

No studies seem to have investigated resistance mechanisms of *S. flexneri* against SCFAs yet. Butyrate has been investigated as a potential therapeutic agent as it counteracts a putative virulence mechanism of *S. flexneri*, namely decreasing LL-37 expression in the gut (177, 178). By suppressing LL-37 expression *S. flexneri* is able to colonize deeper into intestinal crypts (178). Butyrate was able to increase rectal LL-37 expression in a subgroup of patients, which was associated with lower inflammation in rectal mucosa and lower levels of pro-inflammatory cytokines (177). However, butyrate treatment did not seem to impact clinical recovery (177).

The type three secretion system (T3SS) which is able to directly inject bacterial protein into host cells and cause infection, is considered a key virulence factor. *S. flexneri* T3SS can sense and bind secondary bile acid deoxycholate, which leads to co-localization of protein translocators at the needle tip (179, 180). In *S. flexneri* mutants lacking the needle structure, the deoxycholate-associated adhesion and

invasion of *S. flexneri* to host epithelial cells was diminished (181). At physiological levels of bile salts, *S. flexneri* is able to grow normally *in vitro*, but at increased concentrations growth is significantly reduced (182). Transcriptomics showed that during exposure to physiological bile salt levels, genes involved in drug resistance and virulence were upregulated, which was subsequently confirmed using RT-qPCR. Deletion of a multidrug efflux pump led to sensitivity to bile salts and growth inability, confirming the importance of this pump in bile salt resistance (182).

Bacteriocin resistance has not been well studied in *S. flexneri*, but downregulating antimicrobial peptide production in the gut is suggested to be an important virulence mechanism (183). The downregulation of LL-37 early in infection was demonstrated both in gut biopsies of patients and in cell lines (183). Since protein and gene expression were not downregulated to the same degree, the authors speculated that there is an interference mechanism during active transcription of LL-37. Transcription of other antimicrobial peptides was also downregulated, especially in the human β -defensin hBD family (178, 183). It was demonstrated that *S. flexneri* shows high sensitivity to LL-37 and hBD-3 peptides *in vitro* (178). This suggests that by downregulating expression of antimicrobial peptides, *S. flexneri* creates an environment in which it can survive and ultimately cause severe disease.

It is unknown how *S. flexneri* competes and utilizes nutrients in the luminal side of the gut. Therefore, a short description will be given on how the bacterium rewires host cell metabolism for supporting its survival after entering the host cells. These findings might be translatable, and can at least provide insight in potential nutrient usage of *S. flexneri* in the lumen. Using a combination of metabolomics and

proteomics it was demonstrated that *S. flexneri* does not alter host cell metabolism in HeLa cells, but that it captures the majority of the pyruvate output (184). Pyruvate was demonstrated to be a crucial carbon source for *S. flexneri* cultured on a HeLa derivative, using metabolomics, transcriptomics and bacterial mutants (185). *S. flexneri* converts pyruvate into acetate via a very quick, but energy-inefficient pathway, allowing for rapid expansion of the bacterium intracellularly without rapid destruction of the host cell (184).

S. flexneri possess special systems to alter mucus composition. Human colonoid monolayers infected with *S. flexneri* showed increased extracellular release of mucins (186). The increased extracellular mucins were trapped at the cell surface which surprisingly favored access of *S. flexneri* to the apical surface, subsequently promoting cell invasion and cell-to-cell spread (186). Furthermore, expression of several genes encoding for production of mucins and mucin glycosylation patterns were altered (186). Together, these results suggest that *S. flexneri* can alter the mucus environment such that it can promote its own virulence.

C. jejuni

C. jejuni is associated with food-borne gastroenteritis and is estimated to cause more than 800,000 infections annually in the USA alone (187). Major clinical symptoms include diarrhea (both with and without blood), fever and abdominal cramping (160). In rare cases, it can give rise to the Guillain-Barré syndrome and reactive arthritis (187). It is a commensal bacterium in avian species and it is not yet well understood why it causes disease in humans (188).

There is a distinct lack of research on the resistance mechanisms of *C. jejuni* against SCFAs, but one study found that SCFAs are important for colonization in chickens (189). Acetinoogenesis, the conversion of pyruvate to acetate, is a crucial metabolic pathway for optimal colonization of *C. jejuni*. Mutants unable to use this pathway show impaired colonization and decreased expression of acetinoogenesis genes. Upon encountering a mixture of SCFAs at physiological levels, this mutant was surprisingly able to restore acetinoogenesis gene expression to WT levels. Therefore, it was investigated whether expression of acetinogenic genes differs throughout the intestinal tract, as SCFAs are most abundant in distal parts of the intestine. It was observed that both gene expression and *C. jejuni* levels were highest in the cecum. The authors suggested that *C. jejuni* can monitor SCFA levels in the gut, so that in response it can express colonization factors (189). As this is the only study suggesting this hypothesis, further research is required for validation.

Results regarding bile acid resistance in *C. jejuni* are mixed, which may stem from using different animal models or bile acids. A specific multidrug efflux pump, CmeABC, was important for bile resistance in chickens (190). $\Delta cmeABC$ mutants showed impaired growth *in vitro* and unsuccessful colonization in chicken upon cholate administration, while cholate did not affect growth and colonization of the WT (190). This suggests that the efflux pump is critical for proper colonization of *C. jejuni* by mediating bile-acid resistance.

Another study elucidated the effects of secondary bile acids on *C. jejuni* (191). Upon administration of deoxycholate prior to, and during, infection, mice showed decreased colitis. Unexpectedly, *C. jejuni* luminal colonization levels were not

affected (191). In conclusion, *C. jejuni* colonization seems not to be affected by bile acids, but may be important in limiting disease progression.

Bacteriocin resistance is not common in *C. jejuni*. Multiple *C. jejuni* (n=137) isolates were screened for resistance against two anti-*Campylobacter* bacteriocins, OR-7 and E-760, produced by the gut inhabitants *L. salivarius* and *Enterococcus faecium*. However, no isolates were found to harbor resistance (192). In a follow-up study, chickens were successfully colonized with a *C. jejuni* strain prior to bacteriocin treatment, with the aim of studying bacteriocin resistance. Resistance developed in most chickens, but was lost upon ending bacteriocin administration, suggesting resistance instability *in vivo* (193).

In contrast to most other enteric pathogens, *C. jejuni* does not metabolize carbohydrates as its main energy source. It is unable to oxidize glucose, fructose, galactose and several disaccharides, including lactose, maltose and trehalose, resulting from the absence of 6-phosphofructokinase (194-197). Fucose could be metabolized by some *C. jejuni* strains, due to the occurrence of an extra genomic island (197). Main energy sources for *C. jejuni* are organic acids, including acetate, and a limited number of amino acids (198-200). It is currently unclear what these metabolic adaptations mean for its colonization potential, but it is possible that *C. jejuni* occupies a unique macronutrient niche.

Iron regulation systems are critical for colonization and persistence of *C. jejuni*. In presence of sufficient iron, transporter and acquisition genes are downregulated (201). Mutants lacking genes involved in either iron acquisition or transport were severely impaired in colonizing the chick gut (201). Free iron concentrations are

extremely low in the gut, which forces *C. jejuni* to utilize other iron sources. It was demonstrated that lactoferrin and transferrin can also be used for this purpose and molecular pathways have been described (202). In short, transferrin-bound iron can only be utilized if it is in close proximity to the bacterial cell surface. Thereafter, it is most likely that iron is freed from the bacterial cell surface proteins, transported across the outer membrane and subsequently internalized by an ABC-transporter (202). Additionally, both in an *in vitro* setting and in a controlled human infection model with *C. jejuni* the most upregulated genes were involved in iron acquisition (188, 203). These results suggest that iron regulation is maintained extremely well, and that *C. jejuni* can obtain sufficient iron even in a harsh environment as the gut.

C. jejuni resides in the mucus layer prior to invading the epithelial cell. It can cross and reside here because of its powerful flagellum, which can change in conformation or rotation upon being challenged by higher viscosity (204, 205). *C. jejuni* can hereby cross the mucus layer at speeds which cannot be met by other enteric pathogens, and the flagellum can subsequently be used as an adhesin (205, 206).

Another important characteristic for *C. jejuni*'s success in crossing the mucus layer is its helix-shape. In a mouse model, a WT strain or either of two rod shaped *C. jejuni* bacteria, $\Delta pgp1$ or $\Delta pgp2$, were administered to cause infection (207). Rod-shaped mutants were demonstrated to be mostly non-pathogenic, whereas the WT strain caused severe inflammation. Mutants were to some extent able to colonize the mucus layer, but could not cross it, explaining their non-pathogenicity (207).

V. cholerae

V. cholerae is one of the first bacterial pathogens where the microbiota has been considered to play an important role against infection (208). It is mainly prevalent in contaminated brackish or salt water and can cause outbreaks, particularly during wars and after natural disasters. In the first two years following the earthquake in Haiti, 2010, more than 600,000 people were infected with *V. cholerae* serogroup O1, biotype Ogawa, resulting in more than 7,000 deaths (209). The clinical course is characterized by watery diarrhea, which can be so severe that it can result in dehydration, hypovolemic shock and death (210). *V. cholerae* colonizes the small intestine by employing the toxin-coregulated pilus, after which it can cause severe infection and clinical symptoms through cholera enterotoxin production (210).

V. cholerae is able to utilize its acetate switch, the shift from elimination to assimilation of acetate, to increase its own virulence (211). In a *Drosophila* model, it was demonstrated that *crbRS* controlled the acetate switch, while *acs1* was required for acetate assimilation (211). When either of these genes were knocked-out, mortality decreased. Competition experiments demonstrated that WT *V. cholerae* had a growth advantage over $\Delta crbS$ when WT *V. cholerae* was administered in minority. This led the authors to suggest that acetate utilization may be important early in infection, when low levels of *V. cholerae* cells are present (211). Furthermore, acetate consumption led to dysregulation of host insulin signaling pathways, ultimately leading to intestinal steatosis and increased mortality. Dysregulation of host insulin signaling was not observed in $\Delta crbS$ or $\Delta acs1$, further confirming the role of acetate in *V. cholerae* virulence (211).

859 *V. cholerae* has a master regulator, *toxT*, which can directly activate several
860 virulence factors including toxin production. Cholera toxin production was reduced by
861 97% when *V. cholerae* was grown in presence of bile, which could be reversed after
862 growing the same cells in bile-free medium for a few hours (212). *Ctx* and *tcpA*,
863 encoding for cholera toxin and the major structural unit of the toxin-coregulated pilus
864 and regulated by *toxT*, were highly repressed during bile exposure (212).
865 Additionally, motility was increased approximately 1.6-fold in presence of bile (212).
866 To elucidate which exact components of bile acids were responsible for the
867 repression of these virulence genes, bile was fractionated. It was found that several
868 unsaturated fatty acids strongly repressed *ctx* and *tcpA* and that they upregulated
869 expression of *flrA*, leading to increased motility (213). The reason for upregulation of
870 *flrA* and downregulation of *tcpA* could be that the flagellum increases the speed of
871 passing through the mucus layer, while the pilus would only slow it down. When
872 lower concentrations of bile at the epithelial surface are encountered, expression can
873 be reversed (214).

874 Two outer membrane porins, OmpU and OmpT, are directly regulated by the master
875 regulator *toxR*. Upon encountering bile acids, *ompU* and *ompT* are regulated in such
876 a way that bile acid entrance is prevented (215, 216). Furthermore, Δ *toxR* mutants
877 are more sensitive to bile acids due to changed outer membrane composition (215).
878 Recently, it was shown that *toxR* also regulates *leuO* (217). *LeuO* was demonstrated
879 to confer bile resistance independent of the two porins, although its exact resistance
880 mechanism is not yet elucidated (217).

881

882 Bacteriocin resistance in *V. cholerae* has, to our knowledge, not been studied and
883 future studies will have to reveal whether any resistance is present.

884

885 An important nutrient through which *V. cholerae* gains a competitive advantage is
886 sialic acid, a component of the mucus layer. Using streptomycin pre-treated mice
887 who were given a mutant strain defective in sialic acid transport ($\Delta siaM$), it was
888 shown that sialic acid is not required for initial colonization, but that it is important for
889 persistent colonization (218). Competition assays of the two mutant strains in mouse
890 intestine (small intestine, cecum and large intestine) showed that $\Delta siaM$ was less fit
891 to compete in each environment, further indicating the necessity of sialic acid
892 utilization for niche expansion of *V. cholerae* (218).

893 The El Tor strain may have a competitive advantage over 'classical' strains due to its
894 differential carbohydrate metabolism (219). When grown in a glucose-rich medium,
895 classical strains display a growth defect as compared to El Tor. It was observed that
896 this was due to production of organic acids through glucose metabolism, leading to
897 acidification of the medium. El Tor biotypes were found to produce acetoin, a neutral
898 compound, and decrease organic acid production. This prevented acidification of the
899 medium, leading to better growth. El Tor strains were also more successful in
900 colonizing mice, especially when extra glucose was administered. The classical
901 types were shown to be able to produce acetoin, but glucose only led to a minor
902 increase in transcription of genes necessary for acetoin production (219). These
903 studies have shown that specific metabolic pathways are used by *V. cholerae* to
904 successfully colonize the gut.

905

906 One of the first studies on how the mucus layer can potentially be crossed by *V.*
907 *cholerae* was reported almost 50 years ago (220). Here, motile and non-motile
908 strains were compared for pathogenicity after administration to mice. It was observed

that motile strains were almost always deadly 36 hours p.i, while most non-motile strains had a mortality of under 35% (220). One hypothesis offered by the authors was that together with mucinase, the flagellum could effectively pass the mucus barrier (220). Specific mucin degradation mechanisms employed by *V. cholerae* have been identified since, with hemagglutinin/protease (Hap), and TagA being the major ones (221-225). Presence of mucins, limitation of carbon sources and bile acids maximized production of Hap, while glucose could partly reverse this effect (221). This may indicate that during conditions as encountered in the gut, *V. cholerae* quickly aims to cross the mucus layer and be in close contact with the epithelial cells. TagA, which is similar to StcE as described for EHEC, is also capable of degrading mucin (222). In conclusion, *V. cholerae* has developed a way of sensing environmental conditions, and in response to these, is able to upregulate virulence factors which can degrade mucins. A simplified overview of *V. cholerae* virulence factors opposing CR can be found in Fig. 2.

Y. enterocolitica

Yersiniosis is mostly contracted through contaminated food or water with *Y. enterocolitica*, and its prevalence is much higher in developing countries than in high-income nations (160, 226). It is characterized by mild gastroenteritis, abdominal pain and is usually self-limiting, though pseudo-appendicitis illnesses can occur (160). Virulence is mostly conferred through presence of a 64-75 kb plasmid on which several virulence genes are present, including *yadA*, which is crucial for epithelial adherence (227).

Resistance of *Y. enterocolitica* against antibacterial compounds has not been much studied. One study investigated effects of SCFAs on *Y. enterocolitica* at 4°C, including acetic acid and propionic acid. *Y. enterocolitica* was less sensitive to acetic acid when cultured anaerobically as compared to anaerobic culturing. Propionic acid was similarly effective in inhibiting growth with both culture methods (228). Even though conditions like 4°C are not representative for the intestinal environment, this study might provide some initial clues on the effects of SCFAs on *Y. enterocolitica*. It is clear that more research is required to further elucidate potential resistance mechanisms.

OmpR, a transcriptional regulator in *Y. enterocolitica*, is probably able to upregulate expression of the AcrAB-TolC efflux pump, which, in turn, is regulated by two components of the efflux pump, *acrR* and *acrAB* (229). A mixture of bile acids, but not the secondary bile acid deoxycholate, was found to be the strongest inducer of *acrR* and *acrAB* (229). Whether the upregulation of these efflux pump components contributes to bile acid resistance, remains to be elucidated.

Bacteriocin resistance is so far mostly unknown in *Y. enterocolitica*. WA-314 and 8081 are both 1B:O8 strains that are highly infective in murine models (230). WA-314 possesses a putative colicin cluster for colicin production, but no expression was observed in a spot-on-lawn assay with 8081 and the colicin-sensitive *E. coli* K12 (230). It is likely that no specific resistance against colicin is present, as colicin has been shown to effectively inhibit *Y. enterocolitica* infections *in vivo* (59).

957 Like most other enteric pathogens, *Y. enterocolitica* has sophisticated systems to
958 acquire sufficient iron. Using these systems, *Y. enterocolitica* may be more efficient
959 at scavenging iron than commensal members, thereby providing itself with a
960 competitive advantage. *Y. enterocolitica* expresses yersiniabactin, *ybt*, a highly
961 efficient siderophore and a crucial component for lethality in mouse models (231,
962 232). The exact mechanisms for iron uptake and transport have been extensively
963 reviewed elsewhere (233). Proteomics analysis revealed that *Y. enterocolitica*
964 serovar 1A, whose pathogenic role is unclear, uses different proteins to successfully
965 scavenge iron, as it lacks the Ybt protein (234).

966 *Y. enterocolitica* is the only pathogenic Yersinia species which can metabolize
967 sucrose, cellobiose, indole, sorbose and inositol (235). Additionally, it can degrade
968 EA and 1,2-PD by using tetrathionate as a terminal electron acceptor (235).

969

970 Mucus layer invasion and adherence of *Y. enterocolitica* have been elucidated in
971 great detail several decades ago (236-240). The YadA protein is used for initial
972 attachment to the mucus (240). The preferential binding side on mucins is their
973 carbohydrate moiety, but binding to mucin proteins is also possible under specific
974 conditions (238). *Y. enterocolitica* uses a plasmid, pYV, with mucin-degradation
975 enzymes to thin the mucus layer, facilitating crossing of the mucus layer (237, 240).

976 *Y. enterocolitica* containing the pYV plasmid is not only able to successfully invade
977 and degrade the mucus layer, but is also highly efficient in multiplying in this
978 environment (240). After interacting with the mucus layer, its bacterial cell surface
979 was altered so that *Y. enterocolitica* became less efficient in colonizing the brush
980 border (240). This may be a host response mechanism to prevent *Y. enterocolitica*
981 invasion in deeper tissues. In a rabbit infection model, persistent goblet cell

hyperplasia and increased mucin secretion was observed throughout the small intestine over 14 days (236). The extent of hyperplasia was associated with severity of mucosal damage, indicating a compensatory mechanism. Mucin composition changed in infected rabbits, with a decrease in sialic acid and an increase in sulfate (236).

L. monocytogenes

L. monocytogenes causes listeriosis, a food-borne disease. Listeriosis is not highly prevalent, with an estimated 23,150 people infected in 2010 worldwide, but has a high mortality rate of 20-30% (241). The most common syndrome is febrile gastroenteritis, but complications can develop, such as bacterial sepsis and meningitis (241). This is especially relevant for vulnerable patient groups, such as immunocompromised individuals, neonates and fetuses (242). Virulence genes are present on an 8.2-kb pathogenicity island, which includes internalin genes necessary for invading host cells (243).

Culturing *L. monocytogenes* in presence of high levels of butyrate leads to incorporation of more straight-chain fatty acids in the membrane (244, 245). This is not a natural state for *L. monocytogenes*, as normally its membrane consists for a very high percentage of branched-chain fatty acids. When subsequently exposed to LL-37, it displays a survival defect as compared to bacteria not grown in presence of butyrate (244). It was not elucidated whether this survival defect was due to increased stress, altered membrane composition or differentially regulated virulence factors. Effects of propionate on *L. monocytogenes* growth, metabolism and virulence factor expression are dependent on temperature, oxygen availability and

pH (246). Therefore, it is not possible to ascribe a general function to propionate in relation to *L. monocytogenes*.

L. monocytogenes possesses several bile acid resistance mechanisms, and *in vitro* transcriptome and proteome analyses have provided insight into these. Transcriptomics analysis revealed that in response to cholic acid, amongst others, two efflux pumps were upregulated, *mdrM* and *mdrT* (247). BrtA was shown to regulate expression of the efflux pumps, and to be able to sense bile acid levels. Bacterial abundance was determined in multiple organs of mice infected with knockout strains of either efflux pump, but not in the intestine (247). Proteomic analyses found many changes in response to bile salts and included proteins associated with efflux pumps, metabolism and DNA repair (248).

Bile salt hydrolases (BSH) are another way of combatting encountered bile acids. It was demonstrated that all *Listeria* species which infect mammals showed BSH enzyme activity. BSH was crucial during infection of guinea pigs, demonstrated by the decreased ability of Δbsh to cause a persistent infection (249).

At decreased pH levels, e.g. in the duodenum, bile salts are more acidic and show higher toxicity (250). However, this toxicity seems to be strain-dependent (251). The strain responsible for a 2011 outbreak even displayed higher bile resistance at pH 5.5 than at 7.0, further indicating that bile susceptibility may be strain-dependent (251).

As discussed in the introductory section on bacteriocins, the Abp118 bacteriocin produced by *L. salivarius*, protected mice from *L. monocytogenes* infection (55).

However, several bacteriocins have been shown ineffective against *L. monocytogenes* and responsible mechanisms have been partly elucidated. Innate

nisin resistance has been associated with multiple loci (252). One crucial gene was *anrB*, encoding for a permease in an ABC transporter. Loss of this gene resulted in high sensitivity, not only to nisin, but also to several other bacteriocins (252). The mannose phosphotransferase system (Man-PTS), encoded by *mptACD*, is a main sugar uptake system and two of its outer membrane proteins, IIC and IID, can serve as a class II bacteriocin receptor (253). In natural resistant and spontaneous resistant strains, a reduced expression of *mptC* and *mptD* was observed, although this could not be linked to receptor mutations (254). The *mpt* operon is partly regulated by *manR*, and a *manR* mutant did not show any activation of the *mpt* operon (255). Development of bacteriocin resistance was to some extent dependent on available carbohydrates (256). Several sugar sources impaired growth of *L. monocytogenes* when exposed to bacteriocin leucocin A. Increased sensitivity to leucocin A was hypothesized to relate to sugar uptake by Man-PTS. When specific sugars are present, cells may not downregulate this system even in presence of bacteriocins, which possibly allows leucocin A to use the Man-PTS as a docking molecule (256). Not only does *L. monocytogenes* display bacteriocin resistance, it also produces a bacteriocin, Lysteriolysin S, which modifies the gut microbiota such that intestinal colonization is promoted (257). *Allobaculum* and *Alloprevotella*, genera known to contain SCFA-producing strains, were significantly decreased in mice treated with Lysteriolysin S. *L. monocytogenes* strains unable to produce Lysteriolysin S were impaired in competing with native gut microbiota and colonized less efficiently (257).

Most reports about metabolic adaptations of *L. monocytogenes* have logically described intracytosolic adaptations, as *L. monocytogenes* replicates intracellularly

(258). Limited information is available on nutrient competition of *L. monocytogenes* inside the lumen. Comparison of genome sequences between colonizing *Listeria* and non-colonizing *Listeria* led to identification of, amongst others, a vitamin B12-dependent 1,2-propanediol (1,2-PD) degradation pathway in colonizing *Listeria*, dependent on the *pduD* gene (259). Mice were co-infected with a Δ *pduD* strain and a WT strain. Within 3 hours after feeding, a large amount of the Δ *pduD* was shed in feces and 21 hours later the number of viable cells decreased significantly. At ten days p.i, the Δ *pduD* strain was completely cleared, while the WT strain shed for up to four more days. This indicates that the ability to degrade 1,2-PD offers *L. monocytogenes* a distinct competitive advantage (259).

Multiple adhesins and internalins have been characterized which facilitate *L. monocytogenes* retention in the mucus layer (260-263). InlB, InlC, InlL and InlJ were demonstrated to bind to MUC2, but not to epithelial cell surface MUC1 (262, 263). Histopathological analysis of a listeriosis rat model revealed that *L. monocytogenes* was present in the mucus layer after less than 3 hours p.i (261). At this time point, very few *L. monocytogenes* were present on the epithelial cells (261).

Bacterial defense mechanisms against bacteriophages

As research investigating how each enteric pathogen overcomes CR by rendering bacteriophages ineffective is still in its infancy, this general section will describe the most employed resistance mechanisms. The bacteriophage infectious cycle involves a lytic and a lysogenic cycle. Phages have to bind to a receptor on the bacterial surface to be able to insert their genomic material, usually DNA, into the bacterial cytoplasm and subsequently circularize their DNA (264). Here, lysogenic and lytic

bacteriophages' mechanisms start to branch (Fig. 3). Lytic phages start DNA replication, assemble their proteins and pack their DNA into the typical bacteriophage shape with a capsid head and tail. After sufficient replication, phages use lytic enzymes to form holes in the bacterial cell membrane, eventually leading to lysis of the cell and phage spreading. Lysogenic phages integrate their DNA in the bacterial chromosome and become prophages. Reproduction is then ensured through vertical transmission, and upon induction, prophages can also enter the lytic cycle (265) (Fig. 3). In general, factors that induce the lytic phase are compounds or conditions with bactericidal effects, e.g. a DNA damaging-agent (266).

The first step for preventing bacteriophage infection is to prevent surface receptor recognition. Outer membrane vesicles are produced by Gram-negative bacteria and have several functions, including interbacterial communication (267). They have highly similar surface composition as the bacterium and may thereby serve as decoys for attacking phages (268) (Fig. 3). Indeed, *V. cholerae* outer membrane vesicles were shown to neutralize a *V. cholerae* specific phage in a dose-dependent manner (Fig. 2) (268). This effect was only seen when the O1 antigen, the bacteriophage target on *V. cholerae*, was included in the outer membrane vesicle structure (268).

V. cholerae possesses another mechanism to prevent O1 phage receptor recognition (269) (Fig. 3). Two genes necessary for O1 biosynthesis were shown to use phase variation to induce variation in the O1 antigen composition (269). Mutants using phase variation were resistant to the O1 antigen phage, but displayed impaired colonization in a mouse model (269). As the O1 antigen is an important virulence

factor, e.g. for immune evasion, this demonstrates that enteric pathogens constantly have to deal with multiple CR mechanisms (269).

The second step in phage infection is injection of its DNA, and this can be prevented by superinfection exclusion systems which are mostly coded by prophages (Fig. 3). The *E. coli* prophage HK97 encodes for gp15, a probable inner transmembrane protein (270). Remarkably, HK97 gp15 has putative homologues resembling the YebO protein family in many *Enterobacteriaceae* (270). GP15 prevented DNA injection into the bacterial cytoplasm by preventing proper formation of a complex consisting of an inner membrane glucose transporter and part of the tape measure protein (270, 271). This example illustrates how bacteria can incorporate phage DNA to prevent itself against future phage attacks.

DNA replication can be prevented by restriction-modification systems (Fig. 3). These systems consist of a methyltransferase and a restriction endonuclease. Exogenous DNA is not tagged by this methyltransferase, while 'self' DNA does get tagged (272, 273). Subsequently, non-tagged DNA can be cleaved. This system is viewed as a primitive innate bacterial defense system. However, it was found that this system is not perfect, as these restriction-modification systems can also attack self-DNA (274).

Currently, many groups are actively investigating the adaptive bacterial immune system CRISPR-Cas and this has been extensively reviewed elsewhere (275, 276). CRISPR-Cas is present in about 45% of sequenced bacterial genomes, although it is unknown if its prevalence is similar in gut bacteria (277, 278). In short, it consists of CRISPR arrays, sets of short repetitive DNA elements with variable DNA sequences

(spacers) separating the repetitive DNA sets, and of an operon of CRISPR associated genes (Cas). Spacers are pieces of foreign DNA, derived from bacteriophage DNA or other mobile genetic elements such as plasmids. The defense mechanism consists of adaptation followed by expression and interference. During adaptation, Cas proteins can recognize foreign phage DNA and integrate a piece of this DNA as a new spacer into the CRISPR array. This allows the bacterium to build an immunological memory of all phages it previously encountered. The expression response entails transcription of the CRISPR array, followed by processing into smaller RNA pieces (crRNAs). CrRNAs consist of two outer parts of repeated DNA sequences, with a spacer in between. To form the eventual Cas-crRNA complex, crRNAs are combined with at least one Cas protein. This complex then travels through the bacterial cell and when it identifies a complementary DNA sequence, representative for the previously encountered bacteriophage, it cleaves and degrades this foreign DNA.

In 2015, a novel phage resistance system was discovered, called bacteriophage exclusion (BREX) (279). BREX is able to block DNA replication, but does not prevent bacteriophage attachment to the bacterium (Fig. 3). It also uses methylation as guidance to identify self and exogenous DNA, but is different from restriction-modification systems as it does not cleave exogenous DNA (279). Almost 10% of all bacterial genomes sequenced were found to have this BREX, suggesting that it is quite a conserved defense mechanism against bacteriophages (279). In spite of this promising defense mechanism, no further papers have been released regarding BREX functioning in e.g. pathogenic bacteria.

Bacterial cells can perform an apoptosis-like action called abortive infection, resulting in death of the infected cell and hereby protecting surrounding bacterial cells (280) (Fig. 3). These systems have not been much elucidated for enteric pathogens at a molecular level, though, relevance of this system has been shown for the gut bacteria *S. dysenteriae* and *E. coli* (281, 282). The abortive infection systems are best studied in *L. lactis*, a bacterium widely used in production of fermented foods (283).

CONCLUDING REMARKS

Currently, bacterial enteric infections still cause a heavy disease burden worldwide. For many bacterial pathogens, the virulence factors involved in infection are understood, but less is known concerning the failure of gut microbiota to provide colonization resistance against these enteropathogens. A more comprehensive understanding of why the microbiota fail to confer sufficient CR could lead to development of specific therapies aiming to restore CR. It is likely that not a single bacterium will be used as the 'holy grail' to restore CR, but that bacterial consortia with complementary functions will be used instead. This would be preferable over the currently often used FMT, where it is not well known what exact components are transferred to the patient. One could imagine that these consortia could not only be used to treat existing infections, but that they could also be administered prophylactically in susceptible patient groups. In addition, more attention has recently been given to several drugs that were previously not linked to gut health for their potentially disturbing effect on gut microbiota and perhaps CR. In conclusion, we reviewed many of the latest insights in the rapidly evolving fields of gut microbiota,

colonization resistance and bacterial enteric infection. We are looking forward to the coming years, where undoubtedly more knowledge will be gained on gut microbiota and CR, ultimately leading to more microbiota-based therapies.

ACKNOWLEDGEMENTS

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors. B.V.H.H. and E.J.K. are supported by an unrestricted grant from Vedanta Biosciences Inc. W.v.S. is supported by a Royal Society Wolfson Research Merit Award (WM160092). V.B.Y. is supported by grant AI124255 from the National Institutes of Health (United States) and is a consultant for Vedanta Biosciences Inc.

Q.R.D., R.D.Z., B.V.H.H. and E.J.K. designed the structure and content of the review and performed literature research. Q.R.D. wrote the manuscript with guidance from R.D.Z and B.V.H.H. The manuscript was critically reviewed and revised by all authors (Q.R.D., R.D.Z., B.V.H.H., W.v.S., V.B.Y., E.J.K). All authors (Q.R.D., R.D.Z., B.V.H.H., W.v.S., V.B.Y., E.J.K) read and approved the final manuscript.

REFERENCES

1. Sender R, Fuchs S, Milo R. 2016. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol* 14:e1002533.
2. Sommer F, Backhed F. 2013. The gut microbiota--masters of host development and physiology. *Nat Rev Microbiol* 11:227-238.
3. Round JL, Palm NW. 2018. Causal effects of the microbiota on immune-mediated diseases. *Sci Immunol* 3:eaao1603.
4. Opazo MC, Ortega-Rocha EM, Coronado-Arrazola I, Bonifaz LC, Boudin H, Neunlist M, Bueno SM, Kalergis AM, Riedel CA. 2018. Intestinal microbiota influences non-intestinal related autoimmune diseases. *Front Microbiol* 9:432.
5. Li Q, Gao Z, Wang H, Wu H, Liu Y, Yang Y, Han L, Wang X, Zhao L, Tong X. 2018. Intestinal immunomodulatory cells (t lymphocytes): A bridge between gut microbiota and diabetes. *Mediators Inflamm* 2018:9830939.
6. Sadowsky MJ, Staley C, Heiner C, Hall R, Kelly CR, Brandt L, Khoruts A. 2017. Analysis of gut microbiota - An ever changing landscape. *Gut Microbes* 8:268-275.
7. Eckburg PB, Bik EM, Bernstein CN, Purdom E, Dethlefsen L, Sargent M, Gill SR, Nelson KE, Relman DA. 2005. Diversity of the human intestinal flora. *Science* 308:1635-1638.
8. Almeida A, Mitchell AL, Boland M, Forster SC, Gloor GB, Tarkowska A, Lawley TD, Finn RD. 2019. A new genomic blueprint of the human gut microbiota. *Nature*.
9. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, Sogin ML, Jones WJ, Roe BA, Affourtit JP, Egholm M, Henrissat B, Heath AC, Knight R, Gordon JI. 2009. A core gut microbiome in obese and lean twins. *Nature* 457:480-484.
10. Vollaard EJ, Clasener HA. 1994. Colonization resistance. *Antimicrob Agents Chemother* 38:409-414.

1221 11. Becattini S, Littmann ER, Carter RA, Kim SG, Morjaria SM, Ling L, Gyaltshen Y, Fontana E, Taur
1222 Y, Leiner IM, Pamer EG. 2017. Commensal microbes provide first line defense against *Listeria*
1223 *monocytogenes* infection. J Exp Med 214:1973-1989.

1224 12. Martens EC, Neumann M, Desai MS. 2018. Interactions of commensal and pathogenic
1225 microorganisms with the intestinal mucosal barrier. Nat Rev Microbiol 16:457-470.

1226 13. Pickard JM, Zeng MY, Caruso R, Nunez G. 2017. Gut microbiota: Role in pathogen
1227 colonization, immune responses, and inflammatory disease. Immunol Rev 279:70-89.

1228 14. Louis P, Flint HJ. 2017. Formation of propionate and butyrate by the human colonic
1229 microbiota. Environ Microbiol 19:29-41.

1230 15. Rios-Covian D, Ruas-Madiedo P, Margolles A, Gueimonde M, de Los Reyes-Gavilan CG,
1231 Salazar N. 2016. Intestinal short chain fatty acids and their link with diet and human health.
1232 Front Microbiol 7:185.

1233 16. Litvak Y, Byndloss MX, Baumler AJ. 2018. Colonocyte metabolism shapes the gut microbiota.
1234 Science 362.

1235 17. Cummings JH, Pomare EW, Branch WJ, Naylor CPE, Macfarlane GT. 1987. Short chain fatty
1236 acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221-1227.

1237 18. Repaske DR, Adler J. 1981. Change in intracellular pH of *Escherichia coli* mediates the
1238 chemotactic response to certain attractants and repellents. J Bacteriol 145:1198-1208.

1239 19. Roe AJ, O'Byrne C, McLaggan D, Booth IR. 2002. Inhibition of *Escherichia coli* growth by
1240 acetic acid a problem with methionine biosynthesis and homocysteine toxicity. Microbiology
1241 148:2215-2222.

1242 20. Hofmann AF. 1999. The continuing importance of bile acids in liver and intestinal disease.
1243 Arch Intern Med 159:2647-2658.

1244 21. Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal
1245 bacteria. J Lipid Res 47:241-259.

- 1246 22. Buffie CG, Bucci V, Stein RR, McKenney PT, Ling L, Gobourne A, No D, Liu H, Kinnebrew M,
1247 Viale A, Littmann E, van den Brink MR, Jenq RR, Taur Y, Sander C, Cross JR, Toussaint NC,
1248 Xavier JB, Pamer EG. 2015. Precision microbiome reconstitution restores bile acid mediated
1249 resistance to *Clostridium difficile*. Nature 517:205-208.
- 1250 23. Hirano S, Nakam R, Tamaki M, Masuda N, Oda H. 1981. Isolation and characterization of
1251 thirteen intestinal microorganisms capable of 7 alpha-dehydroxylating bile acids. Appl
1252 Environ Microbiol 41:737-745.
- 1253 24. Kang DJ, Ridlon JM, Moore DR, 2nd, Barnes S, Hylemon PB. 2008. *Clostridium scindens* baiCD
1254 and baiH genes encode stereo-specific 7alpha/7beta-hydroxy-3-oxo-delta4-cholenoic acid
1255 oxidoreductases. Biochim Biophys Acta 1781:16-25.
- 1256 25. Sannasiddappa TH, Lund PA, Clarke SR. 2017. In vitro antibacterial activity of unconjugated
1257 and conjugated bile salts on *Staphylococcus aureus*. Front Microbiol 8:1581.
- 1258 26. Kurdi P, Kawanishi K, Mizutani K, Yokota A. 2006. Mechanism of growth inhibition by free
1259 bile acids in lactobacilli and bifidobacteria. J Bacteriol 188:1979-1986.
- 1260 27. Watanabe M, Fukiya S, Yokota A. 2017. Comprehensive evaluation of the bactericidal
1261 activities of free bile acids in the large intestine of humans and rodents. J Lipid Res 58:1143-
1262 1152.
- 1263 28. Thanissery R, Winston JA, Theriot CM. 2017. Inhibition of spore germination, growth, and
1264 toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile
1265 acids. Anaerobe 45:86-100.
- 1266 29. Sayin SI, Wahlstrom A, Felin J, Jantti S, Marschall HU, Bamberg K, Angelin B, Hyotylainen T,
1267 Oresic M, Backhed F. 2013. Gut microbiota regulates bile acid metabolism by reducing the
1268 levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab 17:225-
1269 235.

- 1270 30. Wells EJ, Berr F, Thomas LA, Hermon Dowling R, Dylemon PB. 2000. Isolation and
1271 characterization of cholic acid 7 α -dehydroxylating fecal bacteria from cholesterol gallstone
1272 patients. J Hepatol 32:4-10.
- 1273 31. Sorg JA, Sonenshein AL. 2010. Inhibiting the initiation of *Clostridium difficile* spore
1274 germination using analogs of chenodeoxycholic acid, a bile acid. J Bacteriol 192:4983-4990.
- 1275 32. Studer N, Desharnais L, Beutler M, Brugiroux S, Terrazos MA, Menin L, Schurch CM, McCoy
1276 KD, Kuehne SA, Minton NP, Stecher B, Bernier-Latmani R, Hapfelmeier S. 2016. Functional
1277 intestinal bile acid 7 α -dehydroxylation by *Clostridium scindens* associated with protection
1278 from *Clostridium difficile* infection in a gnotobiotic mouse model. Front Cell Infect Microbiol
1279 6:191.
- 1280 33. Amrane S, Bachar D, Lagier JC, Raoult D. 2018. *Clostridium scindens* is present in the gut
1281 microbiota during *Clostridium difficile* infection: a metagenomic and culturomic analysis. J
1282 Clin Microbiol 56:e01663-17.
- 1283 34. Termen S, Tollin M, Rodriguez E, Sveinsdottir SH, Johannesson B, Cederlund A, Sjoval J,
1284 Agerberth B, Gudmundsson GH. 2008. PU.1 and bacterial metabolites regulate the human
1285 gene CAMP encoding antimicrobial peptide LL-37 in colon epithelial cells. Mol Immunol
1286 45:3947-3955.
- 1287 35. Peric M, Koglin S, Dombrowski Y, Gross K, Bradac E, Ruzicka T, Schaubert J. 2009. VDR and
1288 MEK-ERK dependent induction of the antimicrobial peptide cathelicidin in keratinocytes by
1289 lithocholic acid. Mol Immunol 46:3183-3187.
- 1290 36. Rea MC, Sit CS, Clayton E, O'Connor PM, Whittall RM, Zheng J, Vederas JC, Ross RP, Hill C.
1291 2010. Thuricin CD, a posttranslationally modified bacteriocin with a narrow spectrum of
1292 activity against *Clostridium difficile*. Proc Natl Acad Sci U S A 107:9352-9357.
- 1293 37. Parks WM, Bottrill AR, Pierrat OA, Durrant MC, Maxwell A. 2007. The action of the bacterial
1294 toxin, microcin B17, on DNA gyrase. Biochimie 89:500-507.

- 1295 38. Destoumieux-Garzon D, Peduzzi J, Thomas X, Djediat C, Rebuffat S. 2006. Parasitism of iron-
1296 siderophore receptors of *Escherichia coli* by the siderophore-peptide microcin E492m and its
1297 unmodified counterpart. *Biometals* 19:181-191.
- 1298 39. Mukhopadhyay J, Sineva E, Knight J, Levy RM, Ebright RH. 2004. Antibacterial peptide
1299 microcin J25 inhibits transcription by binding within and obstructing the RNA polymerase
1300 secondary channel. *Mol Cell* 14:739-751.
- 1301 40. Cotter PD, Ross RP, Hill C. 2013. Bacteriocins - a viable alternative to antibiotics? *Nat Rev*
1302 *Microbiol* 11:95-105.
- 1303 41. Rebuffat S. 2011. Bacteriocins from Gram-negative bacteria: A classification?, p 55-72. *In*
1304 Drider D, Rebuffat S (ed), *Prokaryotic Antimicrobial Peptides: From Genes to Applications*.
1305 Springer New York, New York, NY.
- 1306 42. Rea MC, Ross RP, Cotter PD, Hill C. 2011. Classification of bacteriocins from Gram-positive
1307 bacteria, p 29-53. *In* Drider D, Rebuffat S (ed), *Prokaryotic Antimicrobial Peptides: From*
1308 *Genes to Applications*. Springer New York, New York, NY.
- 1309 43. Severina E, Severin A, Tomasz A. 1998. Antibacterial efficacy of nisin against multidrug-
1310 resistant Gram-positive pathogens. *J Antimicrob Chemother* 41:341-347.
- 1311 44. Le Lay C, Dridi L, Bergeron MG, Ouellette M, Fliss IL. 2016. Nisin is an effective inhibitor of
1312 *Clostridium difficile* vegetative cells and spore germination. *J Med Microbiol* 65:169-175.
- 1313 45. Benkerroum N, Sandine WE. 1988. Inhibitory action of nisin against *Listeria monocytogenes*.
1314 *J Dairy Sci* 71:3237-3245.
- 1315 46. Stevens KA, Sheldon BW, Klapes NA, Klaenhammer TR. 1991. Nisin Treatment for
1316 Inactivation of *Salmonella* Species and other gram-negative bacteria. *Appl Environ Microbiol*
1317 57:3613-3615.
- 1318 47. Prudencio CV, Mantovani HC, Cecon PR, Vanetti MC. 2015. Differences in the antibacterial
1319 activity of nisin and bovicin HC5 against *Salmonella* Typhimurium under different
1320 temperature and pH conditions. *J Appl Microbiol* 118:18-26.

1321 48. Singh AP, Prabha V, Rishi P. 2013. Value addition in the efficacy of conventional antibiotics
1322 by nisin against *Salmonella*. PLoS One 8:e76844.

1323 49. Singh AP, Preet S, Rishi P. 2014. Nisin/beta-lactam adjunct therapy against *Salmonella*
1324 *enterica* serovar Typhimurium: a mechanistic approach. J Antimicrob Chemother 69:1877-
1325 1887.

1326 50. Li Q, Montalban-Lopez M, Kuipers OP. 2018. Increasing the antimicrobial activity of nisin-
1327 based lantibiotics against gram-negative pathogens. Appl Environ Microbiol 84:e00052-18.

1328 51. Ritchie JM, Greenwich JL, Davis BM, Bronson RT, Gebhart D, Williams SR, Martin D, Scholl D,
1329 Waldor MK. 2011. An *Escherichia coli* O157-specific engineered pyocin prevents and
1330 ameliorates infection by *E. coli* O157:H7 in an animal model of diarrheal disease. Antimicrob
1331 Agents Chemother 55:5469-5474.

1332 52. Gillor O, Nigro LM, Riley MA. 2005. Genetically engineered bacteriocins and their potential
1333 as the next generation of antimicrobials. Curr Pharm Des 11:1067-1075.

1334 53. Hasper HE, Kramer NE, Smith JL, Hilman JD, Zachariah C, Kuipers OP, de Kruijff B, Breukink E.
1335 2006. An alternative bactericidal mechanism of action for lantibiotic peptides that target
1336 Lipid II. Science 313:1636-1637.

1337 54. Wiedemann I, Breukink E, van Kraaij C, Kuipers OP, Bierbaum G, de Kruijff B, Sahl HG. 2001.
1338 Specific binding of nisin to the peptidoglycan precursor lipid II combines pore formation and
1339 inhibition of cell wall biosynthesis for potent antibiotic activity. J Biol Chem 276:1772-1779.

1340 55. Corr SC, Riedel CU, O'Toole PW, Hill C, Gahan CGM. 2007. Bacteriocin production as a
1341 mechanism for the antiinfective activity of *Lactobacillus salivarius* UCC118. Proc Natl Acad
1342 Sci U S A 104:7617-7621.

1343 56. Rea MC, Dobson A, O'Sullivan O, Crispie F, Fouhy F, Cotter PD, Shanahan F, Kiely B, Hill C,
1344 Ross RP. 2011. Effect of broad- and narrow-spectrum antimicrobials on *Clostridium difficile*
1345 and microbial diversity in a model of the distal colon. Proc Natl Acad Sci U S A 108 Suppl
1346 1:4639-4644.

- 1347 57. Rea MC, Alemayehu D, Casey PG, O'Connor PM, Lawlor PG, Walsh M, Shanahan F, Kiely B,
1348 Ross RP, Hill C. 2014. Bioavailability of the anti-clostridial bacteriocin thuricin CD in
1349 gastrointestinal tract. *Microbiology* 160:439-445.
- 1350 58. Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto
1351 S, Terrapon N, Muller A, Young VB, Henrissat B, Wilmes P, Stappenbeck TS, Nunez G,
1352 Martens EC. 2016. A dietary fiber-deprived gut microbiota degrades the colonic mucus
1353 barrier and enhances pathogen susceptibility. *Cell* 167:1339-1353 e21.
- 1354 59. Bosak J, Micenkova L, Hrala M, Pomorska K, Kunova Bosakova M, Krejci P, Gopfert E, Faldyna
1355 M, Smajs D. 2018. Colicin FY inhibits pathogenic *Yersinia enterocolitica* in mice. *Sci Rep*
1356 8:12242.
- 1357 60. Gillor O, Kirkup BC, Riley MA. 2004. Colicins and microcins: the next generation
1358 antimicrobials. *Adv Appl Microbiol* 54:129-146.
- 1359 61. Sassone-Corsi M, Nuccio SP, Liu H, Hernandez D, Vu CT, Takahashi AA, Edwards RA,
1360 Raffatellu M. 2016. Microcins mediate competition among *Enterobacteriaceae* in the
1361 inflamed gut. *Nature* 540:280-283.
- 1362 62. Rebuffat S. 2012. Microcins in action: amazing defence strategies of Enterobacteria.
1363 *Biochem Soc Trans* 40:1456-1462.
- 1364 63. Walsh CJ, Guinane CM, Hill C, Ross RP, O'Toole PW, Cotter PD. 2015. In silico identification of
1365 bacteriocin gene clusters in the gastrointestinal tract, based on the Human Microbiome
1366 Project's reference genome database. *BMC Microbiol* 15:183.
- 1367 64. Momose Y, Hirayama K, Itoh K. 2008. Competition for proline between indigenous
1368 *Escherichia coli* and *E. coli* O157:H7 in gnotobiotic mice associated with infant intestinal
1369 microbiota and its contribution to the colonization resistance against *E. coli* O157:H7.
1370 *Antonie Van Leeuwenhoek* 94:165-171.
- 1371 65. Fabich AJ, Jones SA, Chowdhury FZ, Cernosek A, Anderson A, Smalley D, McHargue JW,
1372 Hightower GA, Smith JT, Autieri SM, Leatham MP, Lins JJ, Allen RL, Laux DC, Cohen PS,

1373 Conway T. 2008. Comparison of carbon nutrition for pathogenic and commensal *Escherichia*
1374 *coli* strains in the mouse intestine. Infect Immun 76:1143-1152.

1375 66. Maltby R, Leatham-Jensen MP, Gibson T, Cohen PS, Conway T. 2013. Nutritional basis for
1376 colonization resistance by human commensal *Escherichia coli* strains HS and Nissle 1917
1377 against *E. coli* O157:H7 in the mouse intestine. PLoS One 8:e53957.

1378 67. Deriu E, Liu JZ, Pezeshki M, Edwards RA, Ochoa RJ, Contreras H, Libby SJ, Fang FC, Raffatellu
1379 M. 2013. Probiotic bacteria reduce *Salmonella* Typhimurium intestinal colonization by
1380 competing for iron. Cell Host Microbe 14:26-37.

1381 68. Borenstein E, Kupiec M, Feldman MW, Ruppin E. 2008. Large-scale reconstruction and
1382 phylogenetic analysis of metabolic environments. Proc Natl Acad Sci U S A 105:14482-14487.

1383 69. Peterson LW, Artis D. 2014. Intestinal epithelial cells: regulators of barrier function and
1384 immune homeostasis. Nat Rev Immunol 14:141-153.

1385 70. Kashyap PC, Marcobal A, Ursell LK, Smits SA, Sonnenburg ED, Costello EK, Higginbottom SK,
1386 Domino SE, Holmes SP, Relman DA, Knight R, Gordon JI, Sonnenburg JL. 2013. Genetically
1387 dictated change in host mucus carbohydrate landscape exerts a diet-dependent effect on
1388 the gut microbiota. Proc Natl Acad Sci U S A 110:17059-64.

1389 71. Johansson ME, Larsson JM, Hansson GC. 2011. The two mucus layers of colon are organized
1390 by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions.
1391 Proc Natl Acad Sci U S A 108 Suppl 1:4659-4665.

1392 72. Atuma C, Strugala V, Allen A, Holm L. 2001. The adherent gastrointestinal mucus gel layer
1393 thickness and physical state in vivo. Am J Physiol Gastrointest Liver Physiol 280:G922-G929.

1394 73. Schroeder BO, Birchenough GMH, Stahlman M, Arike L, Johansson MEV, Hansson GC,
1395 Backhed F. 2018. Bifidobacteria or fiber protects against diet-induced microbiota-mediated
1396 colonic mucus deterioration. Cell Host Microbe 23:27-40 e7.

1397 74. Jakobsson HE, Rodriguez-Pineiro AM, Schutte A, Ermund A, Boysen P, Bemark M, Sommer F,
1398 Backhed F, Hansson GC, Johansson ME. 2015. The composition of the gut microbiota shapes
1399 the colon mucus barrier. *EMBO Rep* 16:164-177.

1400 75. Keen EC. 2015. A century of phage research: bacteriophages and the shaping of modern
1401 biology. *Bioessays* 37:6-9.

1402 76. Mirzaei MK, Maurice CF. 2017. Ménage à trois in the human gut: interactions between host,
1403 bacteria and phages. *Nat Rev Microbiol* 15:397-408.

1404 77. Wittebole X, De Roock S, Opal SM. 2014. A historical overview of bacteriophage therapy as
1405 an alternative to antibiotics for the treatment of bacterial pathogens. *Virulence* 5:226-235.

1406 78. Yen M, Cairns LS, Camilli A. 2017. A cocktail of three virulent bacteriophages prevents *Vibrio*
1407 *cholerae* infection in animal models. *Nat Commun* 8:14187.

1408 79. Fischer S, Kittler S, Klein G, Glunder G. 2013. Impact of a single phage and a phage cocktail
1409 application in broilers on reduction of *Campylobacter jejuni* and development of resistance.
1410 *PLoS One* 8:e78543.

1411 80. Duerkop BA, Clements CV, Rollins D, Rodrigues JL, Hooper LV. 2012. A composite
1412 bacteriophage alters colonization by an intestinal commensal bacterium. *Proc Natl Acad Sci*
1413 *U S A* 109:17621-17626.

1414 81. Henein A. 2013. What are the limitations on the wider therapeutic use of phage?
1415 *Bacteriophage* 3:e24872.

1416 82. Schooley RT, Biswas B, Gill JJ, Hernandez-Morales A, Lancaster J, Lessor L, Barr JJ, Reed SL,
1417 Rohwer F, Benler S, Segall AM, Taplitz R, Smith DM, Kerr K, Kumaraswamy M, Nizet V, Lin L,
1418 McCauley MD, Strathdee SA, Benson CA, Pope RK, Leroux BM, Picel AC, Mateczun AJ, Cilwa
1419 KE, Regeimbal JM, Estrella LA, Wolfe DM, Henry MS, Quinones J, Salka S, Bishop-Lilly KA,
1420 Young R, Hamilton T. 2017. Development and use of personalized bacteriophage-based
1421 therapeutic cocktails to treat a patient with a disseminated resistant *Acinetobacter*
1422 *baumannii* infection. *Antimicrob Agents Chemother* 61:e00954-17.

- 1423 83. Chan BK, Turner PE, Kim S, Mojibian HR, Eleftheriades JA, Narayan D. 2018. Phage treatment
1424 of an aortic graft infected with *Pseudomonas aeruginosa*. *Evol Med Public Health* 2018:60-
1425 66.
- 1426 84. Keeney KM, Yurist-Doutsch S, Arrieta MC, Finlay BB. 2014. Effects of antibiotics on human
1427 microbiota and subsequent disease. *Annu Rev Microbiol* 68:217-235.
- 1428 85. Becattini S, Taur Y, Pamer EG. 2016. Antibiotic-induced changes in the intestinal microbiota
1429 and disease. *Trends Mol Med* 22:458-478.
- 1430 86. Forgacs I, Loganayagam A. 2008. Overprescribing proton pump inhibitors. *BMJ* 336:2-3.
- 1431 87. Leonard J, Marshall JK, Moayyedi P. 2007. Systematic review of the risk of enteric infection
1432 in patients taking acid suppression. *Am J Gastroenterol* 102:2047-2056.
- 1433 88. Wei L, Ratnayake L, Phillips G, McGuigan CC, Morant SV, Flynn RW, Mackenzie IS,
1434 MacDonald TM. 2017. Acid-suppression medications and bacterial gastroenteritis: a
1435 population-based cohort study. *Br J Clin Pharmacol* 83:1298-1308.
- 1436 89. Hafiz RA, Wong C, Paynter S, David M, Peeters G. 2018. The risk of community-acquired
1437 enteric infection in proton pump inhibitor therapy: systematic review and meta-analysis.
1438 *Ann Pharmacother* 52:613-622.
- 1439 90. Bavishi C, Dupont HL. 2011. Systematic review: the use of proton pump inhibitors and
1440 increased susceptibility to enteric infection. *Aliment Pharmacol Ther* 34:1269-1281.
- 1441 91. Freedberg DE, Toussaint NC, Chen SP, Ratner AJ, Whittier S, Wang TC, Wang HH, Abrams JA.
1442 2015. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a
1443 crossover trial. *Gastroenterology* 149:883-5 e9.
- 1444 92. Imhann F, Bonder MJ, Vich Vila A, Fu J, Mujagic Z, Vork L, Tigchelaar EF, Jankipersadsing SA,
1445 Cenit MC, Harmsen HJ, Dijkstra G, Franke L, Xavier RJ, Jonkers D, Wijmenga C, Weersma RK,
1446 Zhernakova A. 2016. Proton pump inhibitors affect the gut microbiome. *Gut* 65:740-748.

- 1447 93. Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, Sutter JL, Welter
1448 D, Ley RE, Bell JT, Spector TD, Steves CJ. 2016. Proton pump inhibitors alter the composition
1449 of the gut microbiota. *Gut* 65:749-756.
- 1450 94. Takagi T, Naito Y, Inoue R, Kashiwagi S, Uchiyama K, Mizushima K, Tsuchiya S, Okayaama T,
1451 Dohi O, Yoshida N, Kamada K, Ishikawa T, Handa O, Konishi H, Okuda K, Tsujimoto Y, Ohnogi
1452 H, Itoh Y. 2018. The influence of long-term use of proton pump inhibitors on the gut
1453 microbiota: an age-sex-matched case-control study. *J Clin Biochem Nutr* 62:100-105.
- 1454 95. Sieczkowska A, Landowski P, Gibas A, Kaminska B, Lifschitz C. 2018. Long-term proton pump
1455 inhibitor therapy leads to small bowel bacterial overgrowth as determined by breath
1456 hydrogen and methane excretion. *J Breath Res* 12:036006.
- 1457 96. Yasutomi E, Hoshi N, Adachi S, Otsuka T, Kong L, Ku Y, Yamairi H, Inoue J, Ishida T, Watanabe
1458 D, Ooi M, Yoshida M, Tsukimi T, Fukuda S, Azuma T. 2018. Proton pump inhibitors increase
1459 the susceptibility of mice to oral infection with enteropathogenic bacteria. *Dig Dis Sci*
1460 63:881-889.
- 1461 97. Stiefel U, Rao A, Pultz MJ, Jump RL, Aron DC, Donskey CJ. 2006. Suppression of gastric acid
1462 production by proton pump inhibitor treatment facilitates colonization of the large intestine
1463 by vancomycin-resistant *Enterococcus spp.* and *Klebsiella pneumoniae* in clindamycin-
1464 treated mice. *Antimicrob Agents Chemother* 50:3905-3907.
- 1465 98. Imhann F, Vich Vila A, Bonder MJ, Lopez Manosalva AG, Koonen DPY, Fu J, Wijmenga C,
1466 Zhernakova A, Weersma RK. 2017. The influence of proton pump inhibitors and other
1467 commonly used medication on the gut microbiota. *Gut Microbes* 8:351-358.
- 1468 99. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. 2014. Metformin: from mechanisms of
1469 action to therapies. *Cell Metab* 20:953-966.
- 1470 100. Smyth S, Heron A. 2005. Diabetes and obesity: the twin epidemics. *Nature Medicine* 12:75-
1471 80.

1472 101. Forslund K, Hildebrand F, Nielsen T, Falony G, Le Chatelier E, Sunagawa S, Prifti E, Vieira-Silva
1473 S, Gudmundsdottir V, Pedersen HK, Arumugam M, Kristiansen K, Voigt AY, Vestergaard H,
1474 Hercog R, Costea PI, Kultima JR, Li J, Jorgensen T, Levenez F, Dore J, Meta HITc, Nielsen HB,
1475 Brunak S, Raes J, Hansen T, Wang J, Ehrlich SD, Bork P, Pedersen O. 2015. Disentangling type
1476 2 diabetes and metformin treatment signatures in the human gut microbiota. *Nature*
1477 528:262-266.

1478 102. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z,
1479 Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W,
1480 Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony
1481 G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R,
1482 Zheng W, Li S, Yang H, et al. 2012. A metagenome-wide association study of gut microbiota
1483 in type 2 diabetes. *Nature* 490:55-60.

1484 103. Wu H, Esteve E, Tremaroli V, Khan MT, Caesar R, Manneras-Holm L, Stahlman M, Olsson LM,
1485 Serino M, Planas-Felix M, Xifra G, Mercader JM, Torrents D, Burcelin R, Ricart W, Perkins R,
1486 Fernandez-Real JM, Backhed F. 2017. Metformin alters the gut microbiome of individuals
1487 with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug.
1488 *Nat Med* 23:850-858.

1489 104. Zhou HY, Zhu H, Yao XM, Qian JP, Yang J, Pan XD, Chen XD. 2017. Metformin regulates tight
1490 junction of intestinal epithelial cells via MLCK-MLC. *Eur Rev Med Pharmacol Sci* 21:5239-
1491 5246.

1492 105. Deng J, Zeng L, Lai X, Li J, Liu L, Lin Q, Chen Y. 2018. Metformin protects against intestinal
1493 barrier dysfunction via AMPKalpha1-dependent inhibition of JNK signalling activation. *J Cell*
1494 *Mol Med* 22:546-557.

1495 106. Xue Y, Zhang H, Sun X, Zhu MJ. 2016. Metformin improves ileal epithelial barrier function in
1496 interleukin-10 deficient mice. *PLoS One* 11:e0168670.

1497 107. Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez
1498 KC, Dose H, Mori H, Patil KR, Bork P, Typas A. 2018. Extensive impact of non-antibiotic drugs
1499 on human gut bacteria. *Nature* 555:623-628.

1500 108. Morgan AP, Crowley JJ, Nonneman RJ, Quackenbush CR, Miller CN, Ryan AK, Bogue MA,
1501 Paredes SH, Yourstone S, Carroll IM, Kawula TH, Bower MA, Sartor RB, Sullivan PF. 2014. The
1502 antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse.
1503 *PLoS One* 9:e115225.

1504 109. Lieberman LA, Higgins DE. 2009. A small-molecule screen identifies the antipsychotic drug
1505 pimozide as an inhibitor of *Listeria monocytogenes* infection. *Antimicrob Agents Chemother*
1506 53:756-764.

1507 110. Dastidar SG, Chaudhury A, Annadurai S, Roy S, Mookerjee M, Chakrabarty AN. 1995. In vitro
1508 and in vivo antimicrobial action of fluphenazine. *J Chemother* 7:201-206.

1509 111. Jeyaseeli L, Dasgupta A, Dastidar SG, Molnar J, Amaral L. 2012. Evidence of significant
1510 synergism between antibiotics and the antipsychotic, antimicrobial drug flupenthixol. *Eur J*
1511 *Clin Microbiol Infect Dis* 31:1243-1250.

1512 112. Cusotto S, Strain CR, Fouhy F, Strain RG, Peterson VL, Clarke G, Stanton C, Dinan TG, Cryan
1513 JF. 2018. Differential effects of psychotropic drugs on microbiome composition and
1514 gastrointestinal function. *Psychopharmacology (Berl)*.

1515 113. Rogers MA, Greene MT, Young VB, Saint S, Langa KM, Kao JY, Aronoff DM. 2013. Depression,
1516 antidepressant medications, and risk of *Clostridium difficile* infection. *BMC Med* 11.

1517 114. Munita JM, Arias CA. 2016. Mechanisms of antibiotic resistance. *Microbiol Spectr* 4:VMBF-
1518 0016-2015.

1519 115. Davies J, Davies D. 2010. Origins and evolution of antibiotic resistance. *Microbiol Mol Biol*
1520 *Rev* 74:417-433.

1521 116. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM,
1522 Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN,

1523 McDonald LC. 2015. Burden of *Clostridium difficile* infection in the United States. N Engl J
1524 Med 372:825-834.

1525 117. Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. 2016. *Clostridium difficile* infection. Nat
1526 Rev Dis Primers 2:16020.

1527 118. Crobach MJT, Vernon JJ, Loo VG, Kong LY, Pechine S, Wilcox MH, Kuijper EJ. 2018.
1528 Understanding *Clostridium difficile* colonization. Clin Microbiol Rev 31:e00021-17.

1529 119. Keller JJ, Kuijper EJ. 2015. Treatment of recurrent and severe *Clostridium difficile* infection.
1530 Annu Rev Med 66:373-386.

1531 120. Theriot CM, Koenigsnecht MJ, Carlson PE, Jr., Hatton GE, Nelson AM, Li B, Huffnagle GB, J
1532 ZL, Young VB. 2014. Antibiotic-induced shifts in the mouse gut microbiome and metabolome
1533 increase susceptibility to *Clostridium difficile* infection. Nat Commun 5:3114.

1534 121. Lawley TD, Clare S, Walker AW, Stares MD, Connor TR, Raisen C, Goulding D, Rad R,
1535 Schreiber F, Brandt C, Deakin LJ, Pickard DJ, Duncan SH, Flint HJ, Clark TG, Parkhill J, Dougan
1536 G. 2012. Targeted restoration of the intestinal microbiota with a simple, defined
1537 bacteriotherapy resolves relapsing *Clostridium difficile* disease in mice. PLoS Pathog
1538 8:e1002995.

1539 122. Seekatz AM, Theriot CM, Rao K, Chang YM, Freeman AE, Kao JY, Young VB. 2018. Restoration
1540 of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation
1541 in patients with recurrent *Clostridium difficile* infection. Anaerobe 53:64-73.

1542 123. Sorg JA, Sonenshein AL. 2008. Bile salts and glycine as cogerminants for *Clostridium difficile*
1543 spores. J Bacteriol 190:2505-2512.

1544 124. Sorg JA, Sonenshein AL. 2009. Chenodeoxycholate is an inhibitor of *Clostridium difficile* spore
1545 germination. J Bacteriol 191:1115-1117.

1546 125. Wilson KH. 1983. Efficiency of various bile salt preparations for stimulation of *Clostridium*
1547 *difficile* spore germination. J Clin Microbiol 18:1017-1019.

1548 126. Lewis BB, Carter RA, Pamer EG. 2016. Bile acid sensitivity and in vivo virulence of clinical
1549 *Clostridium difficile* isolates. *Anaerobe* 41:32-36.

1550 127. McBride SM, Sonenshein AL. 2011. Identification of a genetic locus responsible for
1551 antimicrobial peptide resistance in *Clostridium difficile*. *Infect Immun* 79:167-176.

1552 128. McBride SM, Sonenshein AL. 2011. The dlt operon confers resistance to cationic
1553 antimicrobial peptides in *Clostridium difficile*. *Microbiology* 157:1457-1465.

1554 129. Jenior ML, Leslie JL, Young VB, Schloss PD. 2017. *Clostridium difficile* colonizes alternative
1555 nutrient niches during infection across distinct murine gut microbiomes. *mSystems*
1556 2:e00063-17.

1557 130. Jenior ML, Leslie JL, Young VB, Schloss PD. 2018. *Clostridium difficile* alters the structure and
1558 metabolism of distinct cecal microbiomes during initial infection to promote sustained
1559 colonization. *mSphere* 3:e00261-18.

1560 131. Collins J, Robinson C, Danhof H, Knetsch CW, van Leeuwen HC, Lawley TD, Auchtung JM,
1561 Britton RA. 2018. Dietary trehalose enhances virulence of epidemic *Clostridium difficile*.
1562 *Nature* 553:291-294.

1563 132. Collins J, Danhof H, Britton RA. 2018. The role of trehalose in the global spread of epidemic
1564 *Clostridium difficile*. *Gut Microbes*:1-6.

1565 133. Ng KM, Ferreyra JA, Higginbottom SK, Lynch JB, Kashyap PC, Gopinath S, Naidu N, Choudhury
1566 B, Weimer BC, Monack DM, Sonnenburg JL. 2013. Microbiota-liberated host sugars facilitate
1567 post-antibiotic expansion of enteric pathogens. *Nature* 502:96-99.

1568 134. Ferreyra JA, Wu KJ, Hryckowian AJ, Bouley DM, Weimer BC, Sonnenburg JL. 2014. Gut
1569 microbiota-produced succinate promotes *C. difficile* infection after antibiotic treatment or
1570 motility disturbance. *Cell Host Microbe* 16:770-777.

1571 135. Zackular JP, Moore JL, Jordan AT, Juttukonda LJ, Noto MJ, Nicholson MR, Crews JD, Semler
1572 MW, Zhang Y, Ware LB, Washington MK, Chazin WJ, Caprioli RM, Skaar EP. 2016. Dietary zinc

1573 alters the microbiota and decreases resistance to *Clostridium difficile* infection. Nat Med
1574 22:1330-1334.

1575 136. Tasteyre A, Barc MC, Collignon A, Boureau H, Karjalainen T. 2001. Role of FliC and FliD
1576 flagellar proteins of *Clostridium difficile* in adherence and gut colonization. Infect Immun
1577 69:7937-7940.

1578 137. McKee RW, Aleksanyan N, Garret EM, Tamayo R. 2018. Type IV pili promote *Clostridium*
1579 *difficile* adherence and persistence in a mouse model of infection. Infect Immun 86:e00943-
1580 17.

1581 138. Ao TT, Feasey NA, Gordon MA, Keddy KH, Angulo FJ, Crump JA. 2015. Global burden of
1582 invasive nontyphoidal *Salmonella* disease, 2010. Emerg Infect Dis 21:941-949.

1583 139. Feasey NA, Dougan G, Kingsley RA, Heyderman RS, Gordon MA. 2012. Invasive non-typhoidal
1584 salmonella disease: an emerging and neglected tropical disease in Africa. Lancet 379:2489-
1585 2499.

1586 140. Coburn B, Li Y, Owen D, Vallance BA, Finlay BB. 2005. *Salmonella enterica* serovar
1587 Typhimurium pathogenicity island 2 is necessary for complete virulence in a mouse model of
1588 infectious enterocolitis. Infect Immun 73:3219-3227.

1589 141. Kwon YM, Ricke SC. 1998. Induction of acid resistance of *Salmonella* Typhimurium by
1590 exposure to short-chain fatty acids. Appl Environ Microbiol 64:3458-3463.

1591 142. Lawhon S, Maurer R, Suyemoto M, Altier C. 2002. Intestinal short-chain fatty acids alter
1592 *Salmonella* Typhimurium invasion gene expression and virulence through BarASirA. Mol
1593 Microbiol 46:1451-1464.

1594 143. Bronner DN, Faber F, Olsan EE, Byndloss MX, Sayed NA, Xu G, Yoo W, Kim D, Ryu S, Lebrilla
1595 CB, Baumler AJ. 2018. Genetic ablation of butyrate utilization attenuates gastrointestinal
1596 *Salmonella* disease. Cell Host Microbe 23:266-273 e4.

1597 144. Jacobson A, Lam L, Rajendram M, Tamburini F, Honeycutt J, Pham T, Van Treuren W, Pruss K,
1598 Stabler SR, Lugo K, Bouley DM, Vilches-Moure JG, Smith M, Sonnenburg JL, Bhatt AS, Huang

1599 KC, Monack D. 2018. A gut commensal-produced metabolite mediates colonization
1600 resistance to *Salmonella* infection. *Cell Host Microbe* 24:296-307 e7.

1601 145. van Velkinburgh JC, Gunn JS. 1999. PhoP-PhoQ-regulated loci are required for enhanced bile
1602 resistance. *Infect Immun* 67:1614-1622.

1603 146. Hernandez SB, Cota I, Ducret A, Aussel L, Casadesus J. 2012. Adaptation and preadaptation
1604 of *Salmonella enterica* to bile. *PLoS Genet* 8:e1002459.

1605 147. Eade CR, Hung CC, Bullard B, Gonzalez-Escobedo G, Gunn JS, Altier C. 2016. Bile acids
1606 function synergistically to repress invasion gene expression in *Salmonella* by destabilizing
1607 the invasion regulator hilD. *Infect Immun* 84:2198-2208.

1608 148. Gänzle MG, Hertel C, Hammes WP. 1999. Resistance of *Escherichia coli* and *Salmonella*
1609 against nisin and curvacin A. *Int J Food Microbiol* 48:37-50.

1610 149. Gillis CC, Hughes ER, Spiga L, Winter MG, Zhu W, Furtado de Carvalho T, Chanin RB, Behrendt
1611 CL, Hooper LV, Santos RL, Winter SE. 2018. Dysbiosis-associated change in host metabolism
1612 generates lactate to support *Salmonella* growth. *Cell Host Microbe* 23:54-64 e6.

1613 150. Stecher B, Robbiani R, Walker AW, Westendorf AM, Barthel M, Kremer M, Chaffron S,
1614 Macpherson AJ, Buer J, Parkhill J, Dougan G, von Mering C, Hardt WD. 2007. *Salmonella*
1615 *enterica* serovar Typhimurium exploits inflammation to compete with the intestinal
1616 microbiota. *PLoS Biol* 5:2177-2189.

1617 151. Rivera-Chavez F, Zhang LF, Faber F, Lopez CA, Byndloss MX, Olsan EE, Xu G, Velazquez EM,
1618 Lebrilla CB, Winter SE, Baumler AJ. 2016. Depletion of butyrate-producing *Clostridia* from the
1619 gut microbiota drives an aerobic luminal expansion of *Salmonella*. *Cell Host Microbe* 19:443-
1620 454.

1621 152. Spiga L, Winter MG, Furtado de Carvalho T, Zhu W, Hughes ER, Gillis CC, Behrendt CL, Kim J,
1622 Chessa D, Andrews-Polymenis HL, Beiting DP, Santos RL, Hooper LV, Winter SE. 2017. An
1623 oxidative central metabolism enables *Salmonella* to utilize microbiota-derived succinate. *Cell*
1624 *Host Microbe* 22:291-301 e6.

1625 153. Thiennimitr P, Winter SE, Winter MG, Xavier MN, Tolstikov V, Huseby DL, Sterzenbach T,
1626 Tsois RM, Roth JR, Baumler AJ. 2011. Intestinal inflammation allows *Salmonella* to use
1627 ethanolamine to compete with the microbiota. *Proc Natl Acad Sci U S A* 108:17480-17485.

1628 154. Faber F, Thiennimitr P, Spiga L, Byndloss MX, Litvak Y, Lawhon S, Andrews-Polymenis HL,
1629 Winter SE, Baumler AJ. 2017. Respiration of microbiota-derived 1,2-propanediol drives
1630 *Salmonella* expansion during colitis. *PLoS Pathog* 13:e1006129.

1631 155. Faber F, Tran L, Byndloss MX, Lopez CA, Velazquez EM, Kerrinnes T, Nuccio SP, Wangdi T,
1632 Fiehn O, Tsois RM, Baumler AJ. 2016. Host-mediated sugar oxidation promotes post-
1633 antibiotic pathogen expansion. *Nature* 534:697-699.

1634 156. Zarepour M, Bhullar K, Montero M, Ma C, Huang T, Velcich A, Xia L, Vallance BA. 2013. The
1635 mucin Muc2 limits pathogen burdens and epithelial barrier dysfunction during *Salmonella*
1636 *enterica* serovar Typhimurium colitis. *Infect Immun* 81:3672-3683.

1637 157. Ganesh BP, Klopfeisch R, Loh G, Blaut M. 2013. Commensal *Akkermansia muciniphila*
1638 exacerbates gut inflammation in *Salmonella* Typhimurium-infected gnotobiotic mice. *PLoS*
1639 *One* 8:e74963.

1640 158. Eppinger M, Cebula TA. 2015. Future perspectives, applications and challenges of genomic
1641 epidemiology studies for food-borne pathogens: A case study of enterohemorrhagic
1642 *Escherichia coli* (EHEC) of the O157:H7 serotype. *Gut Microbes* 6:194-201.

1643 159. Pai CH, Ahmed N, Lior H, Johnson WM, Sims HV, Woods DE. 1988. Epidemiology of sporadic
1644 diarrhea due to verocytotoxin-producing *Escherichia coli*: a two-year prospective study. *J*
1645 *Infect Dis* 157:1054-1057.

1646 160. Carroll KC, Pfaller MA, Landry ML, McAdam AJ, Patel R, Richter SS, Warnock DW. 2019.
1647 *Manual of Clinical Microbiology*, 12th ed, vol 1. ASM Press, Washington D.C.

1648 161. Xiong H, Guo B, Gan Z, Song D, Lu Z, Yi H, Wu Y, Wang Y, Du H. 2016. Butyrate upregulates
1649 endogenous host defense peptides to enhance disease resistance in piglets via histone
1650 deacetylase inhibition. *Sci Rep* 6:27070.

1651 162. Nakanishi N, Tashiro K, Kuhara S, Hayashi T, Sugimoto N, Tobe T. 2009. Regulation of
1652 virulence by butyrate sensing in enterohaemorrhagic *Escherichia coli*. *Microbiology* 155:521-
1653 530.

1654 163. Takao M, Yen H, Tobe T. 2014. LeuO enhances butyrate-induced virulence expression
1655 through a positive regulatory loop in enterohaemorrhagic *Escherichia coli*. *Mol Microbiol*
1656 93:1302-1313.

1657 164. Zumbrun SD, Melton-Celsa AR, Smith MA, Gilbreath JJ, Merrell DS, O'Brien AD. 2013. Dietary
1658 choice affects Shiga toxin-producing *Escherichia coli* (STEC) O157:H7 colonization and
1659 disease. *Proc Natl Acad Sci U S A* 110:E2126-2133.

1660 165. Fukuda S, Toh H, Hase K, Oshima K, Nakanishi Y, Yoshimura K, Tobe T, Clarke JM, Topping DL,
1661 Suzuki T, Taylor TD, Itoh K, Kikuchi J, Morita H, Hattori M, Ohno H. 2011. Bifidobacteria can
1662 protect from enteropathogenic infection through production of acetate. *Nature* 469:543-
1663 547.

1664 166. Kus JV, Gebremedhin A, Dang V, Tran SL, Serbanescu A, Barnett Foster D. 2011. Bile salts
1665 induce resistance to polymyxin in enterohemorrhagic *Escherichia coli* O157:H7. *J Bacteriol*
1666 193:4509-4515.

1667 167. Schamberger GP, Diez-Gonzalez F. 2005. Assessment of resistance to colicinogenic
1668 *Escherichia coli* by *E. coli* O157:H7 strains. *J Appl Microbiol* 98:245-252.

1669 168. Bertin Y, Girardeau JP, Chaucheyras-Durand F, Lyan B, Pujos-Guillot E, Harel J, Martin C.
1670 2011. Enterohaemorrhagic *Escherichia coli* gains a competitive advantage by using
1671 ethanolamine as a nitrogen source in the bovine intestinal content. *Environ Microbiol*
1672 13:365-377.

1673 169. Bertin Y, Deval C, de la Foye A, Masson L, Gannon V, Harel J, Martin C, Desvaux M, Forano E.
1674 2014. The gluconeogenesis pathway is involved in maintenance of enterohaemorrhagic
1675 *Escherichia coli* O157:H7 in bovine intestinal content. *PLoS One* 9:e98367.

1676 170. Miranda RL, Conway T, Leatham MP, Chang DE, Norris WE, Allen JH, Stevenson SJ, Laux DC,
1677 Cohen PS. 2004. Glycolytic and Gluconeogenic Growth of *Escherichia coli* O157:H7 (EDL933)
1678 and *E. coli* K-12 (MG1655) in the Mouse Intestine. *Infection and Immunity* 72:1666-1676.

1679 171. Curtis MM, Hu Z, Klimko C, Narayanan S, Deberardinis R, Sperandio V. 2014. The gut
1680 commensal *Bacteroides thetaiotaomicron* exacerbates enteric infection through
1681 modification of the metabolic landscape. *Cell Host Microbe* 16:759-769.

1682 172. Pacheco AR, Curtis MM, Ritchie JM, Munera D, Waldor MK, Moreira CG, Sperandio V. 2012.
1683 Fucose sensing regulates bacterial intestinal colonization. *Nature* 492:113-7.

1684 173. In J, Foulke-Abel J, Zachos NC, Hansen AM, Kaper JB, Bernstein HD, Halushka M, Blutt S,
1685 Estes MK, Donowitz M, Kovbasnjuk O. 2016. Enterohemorrhagic *Escherichia coli* reduce
1686 mucus and intermicrovillar bridges in human stem cell-derived colonoids. *Cell Mol*
1687 *Gastroenterol Hepatol* 2:48-62 e3.

1688 174. Hews CL, Tran SL, Wegmann U, Brett B, Walsham ADS, Kavanaugh D, Ward NJ, Juge N,
1689 Schuller S. 2017. The StcE metalloprotease of enterohaemorrhagic *Escherichia coli* reduces
1690 the inner mucus layer and promotes adherence to human colonic epithelium ex vivo. *Cell*
1691 *Microbiol* 19:e12717.

1692 175. Kotloff KL, Winickoff JP, Ivanoff B, Clemens JD, Swerdlow DL, Sansonetti PJ, Adak GK, Levine
1693 MM. 1999. Global burden of *Shigella* infections implications for vaccine development. *Bull*
1694 *World Health Organ* 77:651-666.

1695 176. Kotloff KL, Riddle MS, Platts-Mills JA, Pavlinac P, Zaidi AKM. 2018. Shigellosis. *The Lancet*
1696 391:801-812.

1697 177. Raqib R, Sarker P, Mily A, Alam NH, Arifuzzaman ASM, Rekha RS, Andersson J, Gudmundsson
1698 GH, Cravioto A, Agerberth B. 2012. Efficacy of sodium butyrate adjunct therapy in shigellosis
1699 a randomized, double-blind, placebo-controlled clinical trial. *BMC Infect Dis* 12:111.

1700 178. Sperandio B, Regnault B, Guo J, Zhang Z, Stanley SL, Jr., Sansonetti PJ, Pedron T. 2008.
1701 Virulent *Shigella flexneri* subverts the host innate immune response through manipulation of
1702 antimicrobial peptide gene expression. J Exp Med 205:1121-1132.

1703 179. Olive AJ, Kenjale R, Espina M, Moore DS, Picking WL, Picking WD. 2007. Bile salts stimulate
1704 recruitment of IpaB to the *Shigella flexneri* surface, where it colocalizes with IpaD at the tip
1705 of the type III secretion needle. Infect Immun 75:2626-2629.

1706 180. Stensrud KF, Adam PR, La Mar CD, Olive AJ, Lushington GH, Sudharsan R, Shelton NL, Givens
1707 RS, Picking WL, Picking WD. 2008. Deoxycholate interacts with IpaD of *Shigella flexneri* in
1708 inducing the recruitment of IpaB to the type III secretion apparatus needle tip. J Biol Chem
1709 283:18646-18654.

1710 181. Brotcke Zumsteg A, Goosmann C, Brinkmann V, Morona R, Zychlinsky A. 2014. IcsA is a
1711 *Shigella flexneri* adhesin regulated by the type III secretion system and required for
1712 pathogenesis. Cell Host Microbe 15:435-445.

1713 182. Nickerson KP, Chanin RB, Sistrunk JR, Rasko DA, Fink PJ, Barry EM, Nataro JP, Faherty CS.
1714 2017. Analysis of *Shigella flexneri* resistance, biofilm formation, and transcriptional profile in
1715 response to bile salts. Infect Immun 85:e01067-16.

1716 183. Islam D, Bandholtz L, Nilsson J, Wigzell H, Christensson B, Agerberth B, Gudmundsson GH.
1717 2001. Downregulation of bactericidal peptides in enteric infections a novel immune escape
1718 mechanism. Nat Med 7:180-185.

1719 184. Kentner D, Martano G, Callon M, Chiquet P, Brodmann M, Burton O, Wahlander A, Nanni P,
1720 Delmotte N, Grossmann J, Limenitakis J, Schlapbach R, Kiefer P, Vorholt JA, Hiller S, Bumann
1721 D. 2014. *Shigella* reroutes host cell central metabolism to obtain high-flux nutrient supply for
1722 vigorous intracellular growth. Proc Natl Acad Sci U S A 111:9929-9934.

1723 185. Waligora EA, Fisher CR, Hanovice NJ, Rodou A, Wyckoff EE, Payne SM. 2014. Role of
1724 intracellular carbon metabolism pathways in *Shigella flexneri* virulence. Infect Immun
1725 82:2746-2755.

1726 186. Sperandio B, Fischer N, Joncquel Chevalier-Curt M, Rossez Y, Roux P, Robbe Masselot C,
1727 Sansonetti PJ. 2013. Virulent *Shigella flexneri* affects secretion, expression, and glycosylation
1728 of gel-forming mucins in mucus-producing cells. *Infect Immun* 81:3632-3643.

1729 187. Kaakoush NO, Castano-Rodriguez N, Mitchell HM, Man SM. 2015. Global epidemiology of
1730 *Campylobacter* infection. *Clin Microbiol Rev* 28:687-720.

1731 188. Crofts AA, Poly FM, Ewing CP, Kuroiwa JM, Rimmer JE, Harro C, Sack D, Talaat KR, Porter CK,
1732 Gutierrez RL, DeNearing B, Brubaker J, Laird RM, Maue AC, Jaep K, Alcalá A, Tribble DR,
1733 Riddle MS, Ramakrishnan A, McCoy AJ, Davies BW, Guerry P, Trent MS. 2018. *Campylobacter*
1734 *jejuni* transcriptional and genetic adaptation during human infection. *Nat Microbiol* 3:494-
1735 502.

1736 189. Luethy PM, Huynh S, Ribardo DA, Winter SE, Parker CT, Hendrixson DR. 2017. Microbiota-
1737 derived short-chain fatty acids modulate expression of *Campylobacter jejuni* determinants
1738 required for commensalism and virulence. *MBio* 8:e00407-17.

1739 190. Lin J, Sahin O, Michel LO, Zhang Q. 2003. Critical role of multidrug efflux pump CmeABC in
1740 bile resistance and in vivo colonization of *Campylobacter jejuni*. *Infect Immun* 71:4250-4259.

1741 191. Sun X, Winglee K, Gharaibeh RZ, Gauthier J, He Z, Tripathi P, Avram D, Bruner S, Fodor A,
1742 Jobin C. 2018. Microbiota-derived metabolic factors reduce campylobacteriosis in mice.
1743 *Gastroenterology* 154:1751-1763 e2.

1744 192. Hoang KV, Stern NJ, Saxton AM, Xu F, Zeng X, Lin J. 2011. Prevalence, development, and
1745 molecular mechanisms of bacteriocin resistance in *Campylobacter*. *Appl Environ Microbiol*
1746 77:2309-2316.

1747 193. Hoang KV, Stern NJ, Lin J. 2011. Development and stability of bacteriocin resistance in
1748 *Campylobacter* spp. *J Appl Microbiol* 111:1544-1550.

1749 194. Velayudhan J, Kelly DJ. 2002. Analysis of gluconeogenic and anaplerotic enzymes in
1750 *Campylobacter jejuni* an essential role for phosphoenolpyruvate carboxykinase.
1751 *Microbiology* 148:685-694.

1752 195. Line JE, Hiett KL, Guard-Bouldin J, Seal BS. 2010. Differential carbon source utilization by
1753 *Campylobacter jejuni* 11168 in response to growth temperature variation. J Microbiol
1754 Methods 80:198-202.

1755 196. Gripp E, Hlahla D, Didelot X, Kops F, Maurischat S, Tedin K, Alter T, Ellerbroek L, Schreiber K,
1756 Schomburg D, Janssen T, Bartholomäus P, Hofreuter D, Woltemate S, Uhr M, Brenneke B,
1757 Grüning P, Gerlach G, Wieler L, Suerbaum S, Josenhans C. 2011. Closely related
1758 *Campylobacter jejuni* strains from different sources reveal a generalist rather than a
1759 specialist lifestyle. BMC Genomics 12:584.

1760 197. Muraoka WT, Zhang Q. 2011. Phenotypic and genotypic evidence for L-fucose utilization by
1761 *Campylobacter jejuni*. J Bacteriol 193:1065-1075.

1762 198. Velayudhan J, Jones MA, Barrow PA, Kelly DJ. 2003. L-serine catabolism via an oxygen-labile
1763 L-serine Dehydratase is essential for colonization of the avian gut by *Campylobacter jejuni*.
1764 Infect Immun 72:260-268.

1765 199. Wright JA, Grant AJ, Hurd D, Harrison M, Guccione EJ, Kelly DJ, Maskell DJ. 2009. Metabolite
1766 and transcriptome analysis of *Campylobacter jejuni* in vitro growth reveals a stationary-
1767 phase physiological switch. Microbiology 155:80-94.

1768 200. Leach S, Harvey P, Wait R. 1997. Changes with growth rate in the membrane lipid
1769 composition of and amino acid utilization by continuous cultures of *Campylobacter jejuni*. J
1770 Appl Microbiol 82:631-640.

1771 201. Palyada K, Threadgill D, Stintzi A. 2004. Iron acquisition and regulation in *Campylobacter*
1772 *jejuni*. J Bacteriol 186:4714-4729.

1773 202. Miller CE, Rock JD, Ridley KA, Williams PH, Ketley JM. 2008. Utilization of lactoferrin-bound
1774 and transferrin-bound iron by *Campylobacter jejuni*. J Bacteriol 190:1900-1911.

1775 203. Liu MM, Boinett CJ, Chan ACK, Parkhill J, Murphy MEP, Gaynor EC. 2018. Investigating the
1776 *Campylobacter jejuni* transcriptional response to host intestinal extracts reveals the
1777 involvement of a widely conserved iron uptake system. MBio 9:e01347-18.

1778 204. Ferrero R, Lee A. 1988. Motility of *Campylobacter jejuni* in a viscous environment
1779 comparison with conventional rod-shaped bacteria. J Gen Microbiol 134:53-59.

1780 205. Szymanski CM, King M, Haardt M, Armstrong GD. 1995. *Campylobacter jejuni* motility and
1781 invasion of Caco-2 cells. Infect Immun 63:4295-4300.

1782 206. McSweeney E, Walker RI. 1986. Identification and characterization of two *Campylobacter*
1783 *jejuni* adhesins for cellular and mucous substrates. Infect Immun 53:141-148.

1784 207. Stahl M, Fridrich E, Vermeulen J, Badayeva Y, Li X, Vallance BA, Gaynor EC. 2016. The helical
1785 shape of *Campylobacter jejuni* promotes in vivo pathogenesis by aiding transit through
1786 intestinal mucus and colonization of crypts. Infect Immun 84:3399-3407.

1787 208. Freter R. 1955. The fatal enteric cholera infection in the guinea pig, achieved by inhibition of
1788 normal enteric flora. J Infect Dis 97:57-65.

1789 209. Barzilay EJ, Schaad N, Magloire R, Mung KS, Boncy J, Dahourou GA, Mintz ED, Steenland
1790 MW, Vertefeuille JF, Tappero JW. 2013. Cholera surveillance during the Haiti epidemic--the
1791 first 2 years. N Engl J Med 368:599-609.

1792 210. Kaper JB, Morris JG, Jr., Levine MM. 1995. Cholera. Clin Microbiol Rev 8:48-86.

1793 211. Hang S, Purdy AE, Robins WP, Wang Z, Mandal M, Chang S, Mekalanos JJ, Watnick PI. 2014.
1794 The acetate switch of an intestinal pathogen disrupts host insulin signaling and lipid
1795 metabolism. Cell Host Microbe 16:592-604.

1796 212. Gupta S, Chowdhury R. 1997. Bile affects production of virulence factors and motility of
1797 *Vibrio cholerae*. Infect Immun 65:1131-1134.

1798 213. Chatterjee A, Dutta PK, Chowdhury R. 2007. Effect of fatty acids and cholesterol present in
1799 bile on expression of virulence factors and motility of *Vibrio cholerae*. Infect Immun 75:1946-
1800 53.

1801 214. Sengupta C, Ray S, Chowdhury R. 2014. Fine tuning of virulence regulatory pathways in
1802 enteric bacteria in response to varying bile and oxygen concentrations in the gastrointestinal
1803 tract. Gut Pathog 6:38.

1804 215. Provenzano D, Schuhmacher DA, Barker JL, Klose KE. 2000. The virulence regulatory protein
1805 ToxR mediates enhanced bile resistance in *Vibrio cholerae* and other pathogenic *Vibrio*
1806 species. Infect Immun 68:1491-1497.

1807 216. Duret G, Delcour AH. 2010. Size and dynamics of the *Vibrio cholerae* porins OmpU and OmpT
1808 probed by polymer exclusion. Biophys J 98:1820-9.

1809 217. Ante VM, Bina XR, Howard MF, Sayeed S, Taylor DL, Bina JE. 2015. *Vibrio cholerae* leuO
1810 transcription is positively regulated by toxR and contributes to bile resistance. J Bacteriol
1811 197:3499-3510.

1812 218. McDonald ND, Lubin JB, Chowdhury N, Boyd EF. 2016. Host-derived sialic acids are an
1813 important nutrient source required for optimal bacterial fitness in vivo. MBio 7:e02237-15.

1814 219. Yoon SS, Mekalanos JJ. 2006. 2,3-butanediol synthesis and the emergence of the *Vibrio*
1815 *cholerae* El Tor biotype. Infect Immun 74:6547-6556.

1816 220. Guentzel MN, Berry LJ. 1975. Motility as a virulence factor for *Vibrio cholerae*. Infect Immun
1817 11:890-897.

1818 221. Silva AJ, Pham K, Benitez JA. 2003. Haemagglutinin/protease expression and mucin gel
1819 penetration in El Tor biotype *Vibrio cholerae*. Microbiology 149:1883-1891.

1820 222. Szabady RL, Yanta JH, Halladin DK, Schofield MJ, Welch RA. 2011. TagA is a secreted protease
1821 of *Vibrio cholerae* that specifically cleaves mucin glycoproteins. Microbiology 157:516-525.

1822 223. Benitez JA, Spelbrink RG, Silva A, Philips TE, Stanley CM, Boesman-Finkelstein M, Finkelstein
1823 RA. 1997. Adherence of *Vibrio cholerae* to cultured differentiated human intestinal cells an
1824 in vitro colonization model. Infect Immun 65:3474-3477.

1825 224. Booth BA, Boesman-Finkelstein M, Finkelstein RA. 1984. *Vibrio cholerae* hemagglutinin
1826 protease nicks cholera enterotoxin. Infect Immun 45:558-560.

1827 225. Finkelstein RA, Hanne LF. 1982. Purification and characterization of the soluble
1828 hemagglutinin (cholera lectin)(produced by *Vibrio cholerae*. Infect Immun 36:1199-1208.

1829 226. Rahman A, Bonny TS, Stonsaovapak S, Ananchaipattana C. 2011. *Yersinia enterocolitica*:
1830 Epidemiological studies and outbreaks. J Pathog 2011:239391.

1831 227. Bancercz-Kisiel A, Pieczywek M, Lada P, Szweda W. 2018. The most important virulence
1832 markers of *Yersinia enterocolitica* and their role during infection. Genes (Basel) 9:E235.

1833 228. El-Ziney MG, De Meyer H, Debevere JM. 1997. Growth and survival kinetics of *Yersinia*
1834 *enterocolitica* IP 383 O:9 as affected by equimolar concentrations of undissociated short-
1835 chain organic acids. Int J Food Microbiol 34:233-247.

1836 229. Raczkowska A, Trzos J, Lewandowska O, Nieckarz M, Brzostek K. 2015. Expression of the
1837 AcrAB components of the AcrAB-TolC multidrug efflux pump of *Yersinia enterocolitica* is
1838 subject to dual regulation by OmpR. PLoS One 10:e0124248.

1839 230. Garzetti D, Bouabe H, Heesemann J, Rakin A. 2012. Tracing genomic variations in two highly
1840 virulent *Y. enterocolitica* strains with unequal ability. BMC Genomics 13:467.

1841 231. Carniel E, Mazigh D, Mollaret HH. 1987. Expression of iron-regulated proteins in *Yersinia*
1842 species and their relation to virulence. Infect Immun 55:277-280.

1843 232. Heesemann J, Hantke K, Vocke T, Saken E, Rakin A, Stojiljkovic I, Berner R. 1993. Virulence of
1844 *Yersinia enterocolitica* is closely associated with siderophore production, expression of an
1845 iron-repressible outer membrane polypeptide of 65 000 Da and pesitacin sensitivity. Mol
1846 Microbiol 8:397-408.

1847 233. Perry RD, Fetherston JD. 2011. Yersiniabactin iron uptake: mechanisms and role in *Yersinia*
1848 *pestis* pathogenesis. Microbes Infect 13:808-817.

1849 234. Kanaujia PK, Bajaj P, Kumar S, Singhal N, Viridi JS. 2015. Proteomic analysis of *Yersinia*
1850 *enterocolitica* biovar 1A under iron-rich and iron-poor conditions indicate existence of
1851 efficiently regulated mechanisms of iron homeostasis. J Proteomics 124:39-49.

1852 235. Reuter S, Connor TR, Barquist L, Walker D, Feltwell T, Harris SR, Fookes M, Hall ME, Petty NK,
1853 Fuchs TM, Corander J, Dufour M, Ringwood T, Savin C, Bouchier C, Martin L, Miettinen M,
1854 Shubin M, Riehm JM, Laukkanen-Ninios R, Sihvonen LM, Siitonen A, Skurnik M, Falcao JP,

1855 Fukushima H, Scholz HC, Prentice MB, Wren BW, Parkhill J, Carniel E, Achtman M, McNally A,
1856 Thomson NR. 2014. Parallel independent evolution of pathogenicity within the genus
1857 *Yersinia*. Proc Natl Acad Sci U S A 111:6768-6773.

1858 236. Mantle M, Atkins E, Kelly J, Thakore E, Buret A, Gall DG. 1991. Effects of *Yersinia*
1859 *enterocolitica* infection on rabbit intestinal and colonic goblet cells and mucin
1860 morphometrics, histochemistry, and biochemistry. Gut 32:1131-1138.

1861 237. Mantle M, Basaraba L, Peacock SC, Gall DG. 1989. Binding of *Yersinia enterocolitica* to rabbit
1862 intestinal brush border membranes, mucus, and mucin. Infect Immun 57:3292-3299.

1863 238. Mantle M, Husar SD. 1994. Binding of *Yersinia enterocolitica* to purified, native small
1864 intestinal mucins from rabbits and humans involves interactions with the mucin
1865 carbohydrate moiety. Infect Immun 62:1219-1227.

1866 239. Mantle M, Rombough C. 1993. Growth in and breakdown of purified rabbit small intestinal
1867 mucin by *Yersinia enterocolitica*. Infect Immun 61:4131-4138.

1868 240. Paerregaard A, Espersen F, Jensen OM, Skurnik M. 1991. Interactions between *Yersinia*
1869 *enterocolitica* and rabbit ileal mucus growth, adhesion, penetration, and subsequent
1870 changes in surface hydrophobicity. Infect Immun 59:253-260.

1871 241. de Noordhout CM, Devleeschauwer B, Angulo FJ, Verbeke G, Haagsma J, Kirk M, Havelaar A,
1872 Speybroeck N. 2014. The global burden of listeriosis: a systematic review and meta-analysis.
1873 Lancet Infect Dis 14:1073-1082.

1874 242. McLauchlin J. 1990. Human listeriosis in Britain, 1967-85, a summary of 722 cases. Epidemiol
1875 Infect 104:181-189.

1876 243. Roberts AJ, Wiedmann M. 2003. Pathogen, host and environmental factors contributing to
1877 the pathogenesis of listeriosis. Cell Mol Life Sci 60:904-918.

1878 244. Sun Y, Wilkinson BJ, Standiford TJ, Akinbi HT, O'Riordan MX. 2012. Fatty acids regulate stress
1879 resistance and virulence factor production for *Listeria monocytogenes*. J Bacteriol 194:5274-
1880 5284.

1881 245. Julotok M, Singh AK, Gatto C, Wilkinson BJ. 2010. Influence of fatty acid precursors, including
1882 food preservatives, on the growth and fatty acid composition of *Listeria monocytogenes* at
1883 37 and 10degreesC. Appl Environ Microbiol 76:1423-1432.

1884 246. Rinehart E, Newton E, Marasco MA, Beemiller K, Zani A, Muratore MK, Weis J, Steinbicker N,
1885 Wallace N, Sun Y. 2018. *Listeria monocytogenes* response to propionate is differentially
1886 modulated by anaerobicity. Pathogens 7:E60.

1887 247. Quillin SJ, Schwartz KT, Leber JH. 2011. The novel *Listeria monocytogenes* bile sensor BrtA
1888 controls expression of the cholic acid efflux pump MdrT. Mol Microbiol 81:129-142.

1889 248. Payne A, Schmidt TB, Nanduri B, Pendarvis K, Pittman JR, Thornton JA, Grissett J, Donaldson
1890 JR. 2013. Proteomic analysis of the response of *Listeria monocytogenes* to bile salts under
1891 anaerobic conditions. J Med Microbiol 62:25-35.

1892 249. Dussurget O, Cabanes D, Dehoux P, Lecuit M, Consortium TELG, Buchrieser C, Glaser P,
1893 Cossart P. 2002. *Listeria monocytogenes* bile salt hydrolase is a PrfA-regulated virulence
1894 factor involved in the intestinal and hepatic phases of listeriosis. Mol Microbiol 45:1095-
1895 1106.

1896 250. Begley M, Gahan CGM, Hill C. 2002. Bile stress response in *Listeria monocytogenes* LO28:
1897 Adaptation, cross-protection, and identification of genetic loci involved in bile resistance.
1898 Appl Environ Microbiol 68:6005-6012.

1899 251. White SJ, McClung DM, Wilson JG, Roberts BN, Donaldson JR. 2015. Influence of pH on bile
1900 sensitivity amongst various strains of *Listeria monocytogenes* under aerobic and anaerobic
1901 conditions. J Med Microbiol 64:1287-1296.

1902 252. Collins B, Curtis N, Cotter PD, Hill C, Ross RP. 2010. The ABC transporter AnrAB contributes
1903 to the innate resistance of *Listeria monocytogenes* to nisin, bacitracin, and various -lactam
1904 antibiotics. Antimicrob Agents Chemother 54:4416-4423.

1905 253. Diep DB, Skaugen M, Salehian Z, Holo H, Nes IF. 2007. Common mechanisms of target cell
1906 recognition and immunity for class II bacteriocins. Proc Natl Acad Sci U S A 104:2384-2389.

1907 254. Kjos M, Nes IF, Diep DB. 2011. Mechanisms of resistance to bacteriocins targeting the
1908 mannose phosphotransferase system. *Appl Environ Microbiol* 77:3335-3342.

1909 255. Dalet K, Cenatiempo Y, Cossart P, Consortium TELG, Héchard Y. 2001. A sigma(54)-
1910 dependent PTS permease of the mannose family is responsible for sensitivity of *Listeria*
1911 *monocytogenes* to mesentericin Y105. *Microbiology* 147:3263-3269.

1912 256. Balay DR, Ganzle MG, McMullen LM. 2018. The effect of carbohydrates and bacteriocins on
1913 the growth kinetics and resistance of *Listeria monocytogenes*. *Front Microbiol* 9:347.

1914 257. Quereda JJ, Dussurget O, Nahori MA, Ghoulane A, Volant S, Dillies MA, Regnault B, Kennedy
1915 S, Mondot S, Villoing B, Cossart P, Pizarro-Cerda J. 2016. Bacteriocin from epidemic *Listeria*
1916 strains alters the host intestinal microbiota to favor infection. *Proc Natl Acad Sci U S A*
1917 113:5706-5711.

1918 258. Chen GY, Pensinger DA, Sauer JD. 2017. *Listeria monocytogenes* cytosolic metabolism
1919 promotes replication, survival, and evasion of innate immunity. *Cell Microbiol* 19:e12762.

1920 259. Schardt J, Jones G, Muller-Herbst S, Schauer K, D'Orazio SEF, Fuchs TM. 2017. Comparison
1921 between *Listeria sensu stricto* and *Listeria sensu lato* strains identifies novel determinants
1922 involved in infection. *Sci Rep* 7:17821.

1923 260. Mariscotti JF, Quereda JJ, Garcia-Del Portillo F, Pucciarelli MG. 2014. The *Listeria*
1924 *monocytogenes* LPXTG surface protein Lmo1413 is an invasin with capacity to bind mucin.
1925 *Int J Med Microbiol* 304:393-404.

1926 261. Pron B, Boumaila C, Jaubert F, Sarnacki S, Monnet J, Berche P, Gaillard J. 1998.
1927 Comprehensive study of the intestinal stage of listeriosis in a rat ligated ileal loop system.
1928 *Infect Immun* 66:747-755.

1929 262. Linden SK, Bierne H, Sabet C, Png CW, Florin TH, McGuckin MA, Cossart P. 2008. *Listeria*
1930 *monocytogenes* internalins bind to the human intestinal mucin MUC2. *Arch Microbiol*
1931 190:101-104.

1932 263. Popowska M, Krawczyk-Balska A, Ostrowski R, Desvaux M. 2017. InlL from *Listeria*
1933 *monocytogenes* is involved in biofilm formation and adhesion to mucin. Front Microbiol 8.
1934 264. Segev N, Laub A, Cohen G. 1980. A circular form of bacteriophage P1 DNA made in lytically
1935 infected cells of *Escherichia coli*. Virology 101:261-271.
1936 265. Davies EV, Winstanley C, Fothergill JL, James CE. 2016. The role of temperate bacteriophages
1937 in bacterial infection. FEMS Microbiol Lett 363:fnw015.
1938 266. Refardt D, Rainey PB. 2010. Tuning a genetic switch: experimental evolution and natural
1939 variation of prophage induction. Evolution 64:1086-1097.
1940 267. Schwechheimer C, Kuehn MJ. 2015. Outer-membrane vesicles from gram-negative bacteria:
1941 biogenesis and functions. Nat Rev Microbiol 13:605-619.
1942 268. Reyes-Robles T, Dillard RS, Cairns LS, Silva-Valenzuela CA, Housman M, Ali A, Wright ER,
1943 Camilli A. 2018. *Vibrio cholerae* outer membrane vesicles inhibit bacteriophage infection. J
1944 Bacteriol 200:e00792-17.
1945 269. Seed KD, Faruque SM, Mekalanos JJ, Calderwood SB, Qadri F, Camilli A. 2012. Phase variable
1946 O antigen biosynthetic genes control expression of the major protective antigen and
1947 bacteriophage receptor in *Vibrio cholerae* O1. PLoS Pathog 8:e1002917.
1948 270. Cumby N, Edwards AM, Davidson AR, Maxwell KL. 2012. The bacteriophage HK97 gp15
1949 moron element encodes a novel superinfection exclusion protein. J Bacteriol 194:5012-5019.
1950 271. Cumby N, Reimer K, Mengin-Lecreux D, Davidson AR, Maxwell KL. 2015. The phage tail tape
1951 measure protein, an inner membrane protein and a periplasmic chaperone play connected
1952 roles in the genome injection process of E. coli phage HK97. Mol Microbiol 96:437-447.
1953 272. Haberman A, Heywood J, Meselson M. 1972. DNA Modification Methylase Activity of
1954 *Escherichia coli* Restriction Endonucleases K and P. Proc Natl Acad Sci U S A 69:3138-3141.
1955 273. Brockes JP. 1972. The deoxyribonucleic acid modification enzyme of bacteriophage P1.
1956 Biochem J 127:1-10.

1957 274. Pleska M, Qian L, Okura R, Bergmiller T, Wakamoto Y, Kussell E, Guet CC. 2016. Bacterial
1958 autoimmunity due to a restriction-modification system. *Curr Biol* 26:404-409.

1959 275. Mohanraju P, Makarova KS, Zetsche B, Zhang F, Koonin EV, van der Oost J. 2016. Diverse
1960 evolutionary roots and mechanistic variations of the CRISPR-Cas systems. *Science*
1961 353:aad5147.

1962 276. Amitai G, Sorek R. 2016. CRISPR-Cas adaptation: insights into the mechanism of action. *Nat*
1963 *Rev Microbiol* 14:67-76.

1964 277. Touchon M, Bernheim A, Rocha EP. 2016. Genetic and life-history traits associated with the
1965 distribution of prophages in bacteria. *ISME J* 10:2744-2754.

1966 278. Grissa I, Vergnaud G, Pourcel C. 2007. CRISPRFinder: a web tool to identify clustered
1967 regularly interspaced short palindromic repeats. *Nucleic Acids Res* 35:W52-W57.

1968 279. Goldfarb T, Sberro H, Weinstock E, Cohen O, Doron S, Charpak-Amikam Y, Afik S, Ofir G,
1969 Sorek R. 2015. BREX is a novel phage resistance system widespread in microbial genomes.
1970 *EMBO J* 34:169-183.

1971 280. Gross SR. 1953. Abortive Infection of a Strain of *Escherichia Coli* by Coliphage T2. *J Bacteriol*
1972 68:36-42.

1973 281. Fields KL. 1969. Comparison of the action of colicins EI and K on *Escherichia coli* with the
1974 effects of abortive infection by virulent bacteriophages. *J Bacteriol* 97:78-82.

1975 282. Smith HS, Pizer LI, Pylkas L, Lederberg S. 1969. Abortive Infection of *Shigella dysenteriae* P2
1976 by T2 Bacteriophage. *J Virol* 4:162-168.

1977 283. Ainsworth S, Stockdale S, Bottacini F, Mahony J, van Sinderen D. 2014. The *Lactococcus lactis*
1978 plasmidome: much learnt, yet still lots to discover. *FEMS Microbiol Rev* 38:1066-1088.

1979

FIGURE LEGENDS

FIG 1 Outline of gut microbiota-mediated colonization resistance mechanisms. Fiber obtained from the diet is fermented by gut microbiota into short-chain fatty acids (SCFAs). Bacteriocin producers produce bacteriocins capable of targeting a specific pathogen. Primary bile acids can be converted by a very select group of gut microbiota into secondary bile acids, which generally have antagonistic properties against pathogens. Nutrient competition of native microbiota can limit access to nutrients for a pathogen. Specific organisms can use SCFAs, bacteriocins and primary bile acids to increase their virulence, as will be discussed in later sections.

Fig 2 *Vibrio cholerae* uses a wide array of mechanisms to overcome CR. First, it employs its acetate switch to use acetate for upregulating its own virulence. Bacteriocin resistance remains to be mostly elucidated. To protect itself from bacteriophages, *V. cholerae* produces outer membrane vesicles (OMVs) which act as a decoy binding site for the attacking phages (see section: Bacterial defense mechanisms against bacteriophages). Regulation of outer membrane porins is such that they prevent entry of bile acids when they are encountered. By employing specific mucin-degrading enzymes, *V. cholerae* releases sialic acid and subsequently metabolizes it.

Fig 3 Lytic and lysogenic bacteriophage infection cycle with bacterial defense mechanisms. The first two steps (1 and 2) of infection are identical for the lytic and lysogenic cycle, namely phage binding followed by DNA insertion and DNA circularization. The lysogenic cycle then branches off by integrating its DNA into the bacterial chromosome and becoming prophage, thereby ensuring its replication (3b).

2005 Only upon encountering induction factors will the prophage leave the bacterial
2006 chromosome, after which it can enter the lytic cycle (4b and 5b). In the lytic cycle,
2007 phage DNA and protein is replicated and subsequently assembled into full phages
2008 (3a and 4a). The phages then lyse the bacterial cell, are released and can infect
2009 other bacteria (5a). Bacteria possess multiple mechanisms to prevent killing by
2010 bacteriophages, starting with blocking attachment. This can be achieved through
2011 phase variation or production of OMVs. After phage DNA entry, CRISPR-Cas can
2012 recognize this foreign DNA and degrade it. Phage DNA and protein replication can
2013 be prevented by BREX and restriction modification systems, while full phage
2014 assembly can be prevented by abortive infection.

2015





